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Abstract
MOLECULAR MECHANISMS OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Apple Long
Anil K. Rustgi
Esophageal squamous cell cancer (ESCC) is the 6th leading cause of cancer related deaths amongst American
men. Although rare, this disease has a high mortality rate with a 5-year survival of 17%. Incidentally TP53
mutation is the most common genetic alteration in ESCC, along with over expression of EGFR and CYCLIN
D1. We have previously modeled the invasive features of ESCC, through an in vivo-like 3D organotypic
culture system, utilizing primary epithelial cells that have been transformed by overexpression of mutant
TP53 and EGFR. From this model, a RNA microarray was performed to determine critical genes that are
upregulated at the front of invasion. WNT10A was found to be over 4-fold upregulated, along with a WNT-
signaling gene signature in the invasive cells. We additionally found that increased WNT10A expression was
associated with ESCC, compared to normal esophageal tissue and that increased WNT10A staining was
associated with poor prognosis. Functionally, WNT10A was determined to induce increased proliferation,
migration, invasion and stemness properties in transformed esophageal cancer cells. In addition to examining
the oncogenic properties of WNT10A, we also focused on generating an in vivo model of mutant TP53
driven ESCC. We utilized a carcinogen, 4-nitroquinoline 1-oxide (4-NQO), as a challenge to induce genetic
changes in the background of Tp53 mutation, specific to the oral squamous, esophagus and forestomach
tissues. We found preliminarily that TP53 mutation, specifically the R172H mutant, can accelerate
tumorigenesis as compared to loss of TP53 alone. Additionally, when RNA-seq was performed on the tumor
derived TP53R172H/- and TP53-/- cells, we found an increase of genes associated with an epithelial to
mesenchymal transition (EMT), in the TP53R172H/- cells. Mesenchymal genes such as Cdh2, Zeb1, Zeb2,
Twist, and Snail were increased, while epithelial genes such as Cdh1, Epcam, and Krt4 were decreased.
Altogether, we surmise that the TP53 mutant, R172H, can induce gain-of-function (GOF), oncogenic
properties in order to promote tumorigenesis, potentially by inducing an EMT phenotype.
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ABSTRACT 
	  
MOLECULAR MECHANISMS OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA 
 
Apple Long 
Anil K. Rustgi 
Esophageal squamous cell cancer (ESCC) is the 6th leading cause of cancer 
related deaths amongst American men. Although rare, this disease has a high mortality 
rate with a 5-year survival of 17%. Incidentally TP53 mutation is the most common 
genetic alteration in ESCC, along with over expression of EGFR and CYCLIN D1. We 
have previously modeled the invasive features of ESCC, through an in vivo-like 3D 
organotypic culture system, utilizing primary epithelial cells that have been transformed 
by overexpression of mutant TP53 and EGFR. From this model, a RNA microarray was 
performed to determine critical genes that are upregulated at the front of invasion. 
WNT10A was found to be over 4-fold upregulated, along with a WNT-signaling gene 
signature in the invasive cells. We additionally found that increased WNT10A expression 
was associated with ESCC, compared to normal esophageal tissue and that increased 
WNT10A staining was associated with poor prognosis. Functionally, WNT10A was 
determined to induce increased proliferation, migration, invasion and stemness properties 
in transformed esophageal cancer cells. In addition to examining the oncogenic properties 
of WNT10A, we also focused on generating an in vivo model of mutant TP53 driven 
ESCC. We utilized a carcinogen, 4-nitroquinoline 1-oxide (4-NQO), as a challenge to 
induce genetic changes in the background of Tp53 mutation, specific to the oral 
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squamous, esophagus and forestomach tissues. We found preliminarily that TP53 
mutation, specifically the R172H mutant, can accelerate tumorigenesis as compared to 
loss of TP53 alone. Additionally, when RNA-seq was performed on the tumor derived 
TP53R172H/- and TP53-/- cells, we found an increase of genes associated with an epithelial 
to mesenchymal transition (EMT), in the TP53R172H/- cells. Mesenchymal genes such as 
Cdh2, Zeb1, Zeb2, Twist, and Snail were increased, while epithelial genes such as Cdh1, 
Epcam, and Krt4 were decreased. Altogether, we surmise that the TP53 mutant, R172H, 
can induce gain-of-function (GOF), oncogenic properties in order to promote 
tumorigenesis, potentially by inducing an EMT phenotype.  
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Esophageal cancer 
Esophageal cancer is the sixth leading cause of cancer related deaths worldwide 
and the eighth most common cancer type, with an average 5-year survival of 
approximately 15-20% (Altekruse SF et al., 2009). Esophageal cancer can be separated 
into to two major subtypes, with esophageal squamous cell carcinoma (ESCC) being 
more common than esophageal adenocarcinoma (EAC), worldwide. ESCC is most 
prevalent amongst the “Asian esophageal cancer belt”, which spans from the Middle East 
and across China, suggesting multifactorial components of genetics and environment as 
contributors to disease. In the United States, however, EAC is more common and on the 
rise, and currently contributes to 80% of all esophageal cancer cases (Taylor et al., 2013; 
Mao et al., 2011).  
Major risk factors of esophageal cancer include increased age, alcohol use, and 
smoking (Mao et al., 2011). Ethanol primarily inhibits DNA methylation and interacts 
with retinoid metabolism, in order to induce mutations along the aerodigestive tract (Toh 
et al., 2010). Moreover, metabolism of ethanol can lead to further mutagenic properties: 
specifically, in certain Asian populations, that may be deficient for expression of 
aldehyde dehydrogenase 2 (ALDH2), acetaldehyde build-up may occur, leading to bulky 
adduct formation that may escape DNA-repair pathways, and predisposition for ESCC 
(Yokoyama et al., 2002). Chemicals in cigarettes that are particularly carcinogenic 
include the polycyclic aromatic hydramines and N-nitrosamines (Toh et al., 2010). These 
chemicals can induce DNA methylation, bulky DNA-adduct formation along with 
genomic instability. Regional risk factors additionally play a strong role in ESCC, 
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especially in areas throughout the esophageal cancer belt, where alcohol and tobacco use 
is limited. Nitrosamines found in preserved fish and vegetable diets in northeast China 
are major contributors of disease (Napier et al., 2014). In northern Iran, frequent drinking 
of extremely hot tea has been shown to induce caustic injury and inflammation of the 
esophagus, which has been associated with high risk of ESCC (Mao et al., 2011). 
The only known precursors of ESCC include esophageal squamous dysplasia 
(ESD), with severity of ESD highly associated with ESCC incidence. Primarily, ESD is 
characterized by hyperproliferation, nuclear atypia, loss of cellular polarity, and improper 
differentiation of the tissue, without invasion into the basement membrane. Dysplasia 
grading is stratified into low, middle, and high, depending on the level of infiltration of 
the epithelium. When all layers are affected, the pathological grade is considered to be 
esophageal intraepithelial neoplasia (EIN). Once the atypical epithelial cells penetrate the 
underlying lamina propria, it is considered to be invasive squamous cell carcinoma, with 
lymph node dissemination. Once ESCC has occurred, tumors may be of varying 
differentiation and rather heterogenous, with features of keratin pearls, cytokeratin 
bridges, and desmoplasia within the adventitia; ESCC may also be further stratified based 
on differentiation of the tumor, with poorly differentiated tumors correlating with worst 
outcome and shorter survival time (Taylor et al., 2013).  
Prognosis of esophageal cancer highly correlates with staging at diagnosis. 
Commonly, patients present during later stages, when lymphatic and hematogenous 
spread has already occurred. Furthermore, since the esophagus wall lacks a serosa, 
tumors can expand into adjacent structures in the mediastinum and neck. Staging of 
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esophageal cancer is highly dependent on the TNM system.  T staging represents the 
depth into which the tumor has invaded. T1/T2 tumors, which are usually treated with 
surgical resection, indicate tumor invasion into the lamina propria and muscularis, 
respectively. T3/T4 tumors require neoadjuvent therapy, of either chemotherapeutics or 
radiation, prior to surgical resection, if possible. These later stages usually indicates 
invasion into adventitia and adjacent structure. N staging indicates the absence (N0) or 
presence (N1) of periesophageal lymph node involvement, which is best assed by 
endoscopic ultrasound (EUS). N1 automatically indicates requirement of neoadjuvent 
therapy prior to surgical resection. M staging indicates the level of metastatic spread. M0 
indicates no tumor spread, as determined by computer tomography (CT) at the most 
common sites of metastasis: lung, liver and bone. Metastatic spread is stratified further 
into M1a versus M1b, with M1a an indicator of improved survival. M1a indicates spread 
to the celiac and cervical lymph node, where as M1b, which is present in 15 to 20% of 
ESCC diagnosed, indicates distant spread. All together staging is extremely important in 
determining therapeutics and must be assessed appropriately with a variety of modalities, 
such as CT, EUS, and 18F-fluordeoxyglucos positron emission tomography (FDG-PET) 
(Rice et al., 2010; Napier et al., 2014).  
 A vast majority of genes and dysregulated proteins have been associated with 
ESCC occurrence and prognosis. The most common genetic alterations of ESCC include 
overexpression of Epidermal Growth Factor Receptor (EGFR), CYCLIND1, mutation in 
TP53, and inactivation of p15INK4B/p16INK4A, and loss or mislocalization of p120 
CATENIN and CADHERIN-1 (E-CADHERIN) (Mandard et al., 2000; Stairs et al., 
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2011; Lin et al., 2009).  Recent sequencing efforts have additionally shown that 
NOTCH1, NOTCH3, and FBXW7 were quite frequently mutated in ESCC, along with 
members of the WNT/B-Catenin signaling pathway (Song et al., 2014). Our lab has 
additionally previously shown the importance of PERIOSTIN in mediating migration, 
invasion, and as a diagnostic marker of ESCC (Michaylira et al., 2010; Wong et al., 
2013b; a). One of the most drastic genetic alterations in ESCC is associated with TP53 
loss or mutation. Overall, TP53 is estimated to be mutated in 40-50% of all cases of 
ESCC. Yet, recent sequencing efforts of ESCC in the Chinese population report 
exceedingly high rates of TP53 mutation, from 83 to 93%, with a predominance of 
missense mutations (Song et al., 2014; Gao et al., 2014). Most common missense 
mutations within TP53 include R175H and R248H, which account for 10% of all TP53 
alterations, combined (Petitjean et al., 2007). As TP53 mutation is the most often mutated 
gene in ESCC, it is not surprising that it is suspected to be an early event during 
pathogenesis. Based on immunohistochemistry (IHC) staining along with sequencing of 
microdissected tissue, TP53 mutations are seen even during early dysplasia, suggesting 
TP53 mutation may be an initial driver of ESCC progression (Wang et al., 1993).  
Embryogenesis of the esophagus 
	  
 The esophagus originates as a joint structure with the trachea in a developmental 
intermediate known as the anterior foregut. This foregut is derived by ventral folding of 
the endodermal epithelial sheet during gastrulation (Wells and Melton, 1999). The 
separation of these two structures requires well-coordinated cues from 
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epithelial/mesenchymal interactions as well as specific cell intrinsic cues to proliferate 
and differentiate. Failure of these processes can lead to malformation and birth defects 
such as esophageal atresia and tracheoesophageal fistula.  
The anterior foregut separates in a ventral/dorsal manner, giving rise to the 
trachea and esophagus, respectively. Specific transcription factor expression cues the 
distinction between these two tissues; SOX-2 is expressed in the epithelial cells of the 
dorsal region, whereas NKX2.1 marks the ventral epithelium (Que et al., 2007; Harris-
Johnson et al., 2009). These transcription factors are critical for these cell fate decisions, 
as hypomorph mutations in SOX-2 and deletion of NKX2.1 can lead to esophageal 
atresia and fistulation (Que et al., 2007; Minoo et al., 1999). Extrinsic signaling factors, 
such as WNT signaling (which will be covered more in depth in a later chapter) and bone 
morphogenic protein (BMP) signaling have also shown to play a role in this process, as 
defects in their signaling also produce esophageal atresia phenotypes in mice (Rodriguez 
et al., 2010).   
Following separation of the dorsal foregut, a ciliated simple columnar lumen is 
formed as a precursor to the esophageal stratified epithelium (Yu et al., 2005). SOX-2 
here plays a critical role in inducing the proliferation and stratification of the epithelial 
cells, as SOX-2 hypomorph mutant mice maintain columnar structure and develop 
goblet-like mucin producing cells (Que et al., 2007). Similarly, TP63 null mice also 
exhibit a similar phenotype in the proximal forestomach, which recapitulates the distal 
gastroesophageal junction in humans (Daniely et al., 2004; Wang et al., 2011). TP63 is 
another critical factor in the induction of stratification of epithelium in both skin and 
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esophagus, through its role in maintaining the self-renewal capacity of stratified 
epithelial. TP63 null mice notably are born with little or eroded epithelium (Parsa et al., 
1999; Yang et al., 1999). Interestingly, BMP signaling is silenced during the stratification 
of the esophageal epithelium, as it may negatively regulate SOX-2 expression, but it is re-
expressed shortly after stratification in the suprabasal layers of the esophagus in order to 
allow for proper differentiation of the tissue (Domyan et al., 2011; Rodriguez et al., 
2010).  
TP53: A potent tumor suppressor  
	  
TP53 was first described as a protein associated with the simian virus 40 large T 
antigen in virally transformed cells (Lane and Crawford, 1980; Linzer and Levine, 1979). 
Initial descriptions of TP53 suggested that it was acting as an oncogene, as it became 
upregulated when cell lines were transformed by viruses, irradiation or chemical 
carcinogens. Furthermore, its overexpression was able to immortalize primary cells and 
transform them in cooperation with the expression of Ras (Eliyahu et al., 1984). In 
actuality, the original clone of TP53 studied was actually a mutant version (DeLeo et al., 
1979; Rotter, 1983). Thus, the wildtype version of the protein was indeed a tumor 
suppressor that would become upregulated in response to cellular insults.  
TP53 encodes a tetrameric multidomain protein that is important in responding to 
a variety of stress signals, such as genotoxic damage, oncogene activation, and loss of 
normal cell contact, amongst others (Lane, 1992; Vousden and Prives, 2009). While 
primarily a nuclear transcription factor, capable of activating and repressing downstream 
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target genes, TP53 has additionally been described to have non-transcriptional functions. 
TP53 is composed of three domains: an N-terminal trans-activating (TA) domain, a 
central DNA-binding domain (DBD) and a C-terminal oligomerization domain (OD) 
(Bullock and Fersht, 2001). Almost every amino acid of TP53 can be modified by 
posttranslational modifications, such as phosphorylation, acetylation, ubiquitination, 
amongst others, in order to initiate downstream tumor suppressing functions (Meek and 
Anderson, 2009). TP53 has been shown to participate in a myriad of functions, including 
induction of apoptosis, senescence, cell cycle arrest, DNA damage response, autophagy, 
metabolism, miRNA transcription, and inhibition of embryonic cell reprogramming, thus 
making TP53 such a potent tumor suppressor (Vousden and Prives, 2009).  
Not unexpectedly, TP53 is the most mutated gene in cancer, and is estimated to be 
mutated in over 50% of all cancers. Additionally, individuals with germ line mutations in 
TP53 have a cancer predisposition syndrome, known as Li-Fraumeni syndrome. Over 
70% of TP53 mutations in cancers are missense mutations and 30% of them fall within 
one of six hotspot codons in the DBD (Petitjean et al., 2007). The mutations of TP53 
generally fall into three categories. (1) Nonsense mutations, which account for the 
minority of mutations in esophageal cancer, induce loss of production of full-length 
protein. These mutations, when homozygote, lead to TP53 null cells, which do not have 
the ability to induce a TP53 tumor-suppression response. (2) Single amino acid 
alterations that lead to missense mutations can also cause loss of wildtype TP53 
functions. Additionally though, they can also act in a dominant negative fashion if there 
is maintenance of the second wildtype allele. Since TP53 binds to DNA in a tetrameric 
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fashion, one mutated allele can induce hetero-oligermerization to inhibit proper DNA 
binding. Of note, mutations in TP53 confer increased stability compared to their wildtype 
counterparts due to a combination of mechanisms, which are not completely understood. 
Nevertheless, stabilization of the mutant copy over the wildtype protein of TP53 induces 
a majority of defunct tetramers. Lastly, a newly accepted notion of mutant TP53 is its (3) 
gain-of-function (GOF) oncogenic properties. Given the high propensity of TP53 
missense mutations across many cancers, it has been suggested that certain mutations, 
specifically at the hotspot codons, can provide greater survival advantage, through GOF 
oncogenic properties. GOF is especially apparent when there is loss of heterozygosity of 
the second TP53 allele, in order to ensure that no dominant negative effects can occur. 
Therefore, in order to most rigorously study GOF properties of mutant TP53, 
investigators must perform all studies under TP53 null conditions (Brosh and Rotter, 
2009; Oren and Rotter, 2010; Freed-Pastor and Prives, 2012; Oren and Rotter, 2015).  
Gain of function roles of mutant TP53 
	  
GOF mutations in the DBD region of TP53 are most common, as they cause TP53 
to lose its specificity to DNA sequences, while maintaining transactivation functions 
(Petitjean et al., 2007). These mutations can either cause global conformation changes or 
interfere with promoter-specific contact. The R175H mutation, a hotspot mutation, for 
instance, causes destabilization at a zinc-binding site, which structurally distorts the 
conformation of TP53 (Olivier et al., 2010). This mutant may even expose hydrophobic 
epitopes that can aggregate into large Β-sheaths that may act as a sponge for other 
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proteins. R273H, on the other hand is a contact defective mutant, which cannot bind the 
canonic TP53 DNA-binding sites in a sequence specific fashion (Xu et al., 2011). Other 
hotspot mutations include G245S, R248W, R249S and R282S (Petitjean et al., 2007). 
The prevalence of hotspot mutation sites suggests a specific survival advantage for these 
mutations, and thus potentially oncogenic potential of these specific mutants. 
Additionally, in esophageal cancer, up to 75% of all tumors with TP53 mutation have 
coinciding additional alterations of the second allele (either mutated or promoter 
methylated), suggesting that GOF properties may be highly prevalent (Hu et al., 2001).   
Some of the first studies to implicate GOF roles of mutant TP53 occurred over 20 
years ago. When TP53 null fibroblasts were transfected with mutant TP53, it was shown 
that mutant TP53 overexpressing cells had a greater propensity for forming tumors in null 
mice, compared to the TP53 null fibroblasts. Transfection of mutant TP53 in a null 
human osteosarcoma line also induce greater soft agar plating efficiency, as compared to 
the control (Dittmer et al., 1993). This seminal study implicated the potential for 
additional oncogenic functions of mutant TP53 and led to decades more of continuing 
researching into the mutant TP53 GOF field. In 2004, two groups showed through 
independent mouse models the in vivo GOF effects of mutant TP53.  Each group 
expressed a knock-in mutation of TP53 at the endogenous promoter, which can be 
induced by a tissue specific Cre-Lox system. In a 129S4/SVJae background, mice, with 
Protamine-Cre induced knock-in mutations of R172H and R270H of TP53 (equivalent to 
R175H and R273H respectively in the human), mice developed carcinomas at higher 
frequencies, when compared to TP53 null mice, although lifespan of mice were 
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equivalent. While most TP53 null mice succumbed to hematological illness, almost none 
developed carcinomas, suggesting the necessity of mutations in TP53 in order to induce 
transformation in epithelial cells (Olive et al., 2004). In the C57BL/6 background of 
knock-in p53R172H mice, there were no differences in tumor site spectra between mutant 
TP53 mice and TP53 null mice. Instead, there was a greater predilection for the mutant 
TP53 knock-in mice to develop metastases, as compared to the null controls (Lang et al., 
2004). This phenomenon is reinforced in recent metastasis models utilizing cells derived 
from murine pancreatic cancer driven by KRASG12D and TP53R172H  mutations. When 
these cells were deprived of mutant TP53, there was a decreased propensity of these cells 
to colonize into the lungs and liver when injected orthotopically into pancreata. The 
mechanism by which mutant TP53 induced increased metastases was shown to be 
through repression of TP73/NF-Y complex leading to induction of PDGFΒ 
(Weissmueller et al., 2014).  
Studies on GOF mutant TP53 indicate that the oncogenic properties of mutant 
TP53 can arise from a variety of mechanisms.  Specifically, mutant TP53 has been shown 
to participate in novel protein-protein interactions, trans-activate novel gene targets, or a 
combination of the two. Additionally, since mutant TP53 is normally expressed at rather 
high protein concentrations due to its inability to be properly degraded, normally weak 
protein-protein interactions can be exacerbated. When mutant TP53 participates in novel 
protein-protein interactions, it can either inhibit or potentiate the functions of the binding 
partner. Proteins that mutant TP53 have been shown to inhibit include MRE11 and the 
TP53 family members, TP63 and TP73 (Freed-Pastor and Prives, 2012). Inhibition of 
	  
	  
12	  
MRE11, for instance inhibits its proper binding to the MRE11-NBS-RAD50 complex, 
which is required for proper ATM-mediated DNA-repair. Thus mutant TP53 can 
potentiate genomic instability in its GOF role (Song et al., 2007). TP53 interaction with 
various isoforms of TP63, via the DNA-binding domain can initiate a pro-invasive 
phenotype, either through activation of downstream TP63 targets or through induction of 
an integrin recycling pathway (Adorno et al., 2009; Muller et al., 2009). Additionally, 
mutant TP53 can interact with a variety of transcription factors in order to be recruited to 
their discrete binding sites. In turn, mutant TP53 can either trans-activate or repress these 
downstream gene targets as its trans-activation domain is not commonly mutated (Freed-
Pastor and Prives, 2012; Muller and Vousden, 2013). These trans-activation domains are 
capable of recruiting transcriptional activators such as p300 and TATA binding protein, 
in order to induce transcription of novel targets (Di Agostino et al., 2006; Liu et al., 2011; 
Dell’Orso et al., 2011). Transcription factors that have been shown to co-opt mutant 
TP53’s transactivation functions include NF-Y, SP1, ETS-2, VDR, and SREBP2 (Liu et 
al., 2011; Chicas et al., 2000; Do et al., 2012; Stambolsky et al., 2010; Freed-Pastor et al., 
2012) . Downstream functions of mutant TP53 can lead to a variety of transforming roles 
including: migration, invasion, proliferation, drug resistance, and induction of genomic 
instability (Freed-Pastor and Prives, 2012).  
Role of mutant TP53 in 3D organotypic culture of transformed esophageal cells 
	  
 Considering the high prevalence of mutations in TP53 in ESCC, our lab generated 
cells lines that overexpressed the different TP53 mutations in a transformed setting. 
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Primary normal epithelial esophageal cells (EPC2) were obtained from a human biopsy, 
and were immortalized by the overexpression of hTERT (Harada et al., 2003). These 
immortalized, EPC2-hTERT cells could be further transformed by the expression of a 
combination of oncogenes, such as overexpression of EGFR and mutations in TP53 
(Okawa et al., 2007). Of note, the wildtype allele of TP53 was maintained in these cells, 
while the mutant allele was transgenically overexpressed. These cells were shown to be 
transformed by a variety of mechanisms such as through migration, invasion, colony 
formation, soft agar growth, and xenograft implant assays (Okawa et al., 2007).  
Furthermore, these cells were grown in an in vivo-like 3D organotypic culture 
system (OTC), which recapitulated the microenvironment of epithelial cells of the 
esophagus (Michaylira et al., 2010). This 3D OTC system consists of a bottom 
matrigel/collagen acellular layer, which is overlaid with low passage fetal esophageal 
fibroblasts in the middle layer. After seven days, these layers contract into a feeder 
matrix, and epithelial cells can be grown on top. These cells can divide in an 
asymmetrical fashion in order to induce the stratified layer of the esophageal epithelium. 
Furthermore, upon introducing an air-liquid interface, the stratified epithelium can induce 
keratinization, which is seen in human skin and mouse esophagus. These 3D culture 
systems can be harvested and embedded into paraffin blocks in order to allow for 
Hematoxylin and Eosin (H&E) and/or immunohistochemistry (IHC) staining (Kalabis et 
al., 2012).  
 Although the transformed EPC2-hTERT derivatives that have overexpression of 
mutant TP53 can induce stratification in this 3D OTC system, they additionally show 
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features of invasive downward growth into the fibroblast-enriched matrix. Primarily these 
invasive regions are not differentiated and maintain basal cell features, such as strong 
TP63 staining, a marker of the undifferentiated epithelial cell (Okawa et al., 2007). 
Interestingly, there are different degrees of invasion, with the R175H mutation being the 
most invasive. This process was further explored, in order to better understand some of 
the mechanisms of mutant TP53-mediated invasion, as a potential GOF property. In order 
to do so, our lab utilized laser-capture microdisecction of the invasive and non-invasive 
regions of the 3D OTC samples that grew different TP53 mutations (R175H, R248W, 
R273H and V143A).  We proceeded to harvest RNA from each these sections in order to 
perform comparative microarray analysis on the invasive and non-invasive region. One of 
the top genes that was upregulated in each microarray set was PERIOSTIN, a 
matricellular protein that not only was induced by mutant TP53, but also worked in 
concert with mutant TP53 in order to induce a permissive microenvironment to induce 
invasion (Ohashi et al., 2010a; Michaylira et al., 2010; Wong et al., 2013b).  
Additional pathway analysis was performed on the invasive gene signature, and 
from the combination of all the mutants, it was shown that there was a significant 
enrichment of the WNT signaling gene signature. Specifically, genes such as WNT10A 
and WNT5B were upregulated, while the WNT signaling negative regulator DKK1 was 
downregulated across multiple mutants (Long et al., 2015). As the WNT signaling 
pathway is frequently dysregulated in over 40% of all ESCC (Song et al., 2014), we 
decided to investigate this pathway further, specifically via WNT10A. WNT10A 
upreguulation was not only associated in the WNT signaling pathway, but also 
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contributed to other significantly enriched pathways, associated with the invasive gene 
signature, such as regulation of the epithelial to mesenchymal transition pathway and 
induction of human embryonic stem cell pluripotency.  
WNTs and the canonical WNT pathway 
 The WNT family of ligands is critical in both development and disease across all 
metazoan species, with conservation from the Hydra vulgaris to the higher vertebrates 
(Kusserow et al., 2005). Wnt1 was first cloned in 1982, under the name int1. Notably, 
int1 was a common insertion site for the retrovirus, Mouse Mammary Tumor Virus; this 
specific insertion could induce the upregulation of the proto-oncogene Wnt1, in order to 
induce transformation of mouse mammary tissue (Nusse and Varmus, 1982). 
Concurrently, developmental biologists, studying Drosophila melanogaster, were able to 
generate mutants that disrupted segment polarity in embryonic development. Wingless 
was (Wg), was one of the genes discovered in this mutant screen, along with Armadillo, 
Dishevelled, Porcupine, and Arrow (Sharma and Chopra, 1976; Nüsslein-Volhard and 
Wieschaus, 1980). Indeed, the Drosophila homologue of int1 mapped closely to 
Wingless, with a similar localization pattern of a striped larvae . By the 1990s, the naming 
of the gene combined, to form ‘WNT’ (Wingless-related integration site), with Wnt1 
(int1) becoming the first member of a family of related genes (Nusse et al., 1991).  
 Mice and humans have over 19 members in the WNT family, which fall into 
twelve subgroups. Between mouse and human, WNTs are conserved 99% at the amino 
acid level.  While at least eleven WNTs existed in the last common ancestor between 
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deuterstomes and arthopods, duplication events occurred over the last 500 million years, 
in order to generate many of the paralogs of WNT 3, 5, 7 and 10 (Sidow, 1992). 
Interestingly, Drosophila and Caenorhabditis lost some of their WNT homologs, and 
only have seven and five WNTs, respectively. WNT10 was duplicated along with the 
WNT1-WNT6-WNT10 cluster. Over time, WNT6 was lost from the WNT1-WNT10B 
cluster, where as WNT1 was lost from in the WNT6-WNT10A cluster (Nusse, 2001). 
Maintenance of two different WNT10 genes may suggest diverse and specific functions of 
these two genes in higher organisms, although redundant roles may still exist. 
Additionally, this unique grouping of WNT genes suggests coordinated regulation of 
each cluster, similar to another developmental grouping, the Hox cluster. 
 Members of the WNT family are small, secreted proteins, which are cysteine-rich. 
Many of these cysteine sites are predicted to form disulfide bonds in order to maintain the 
globular structure of WNT. In addition, WNTs are also highly post-translationally 
modified with various glycosylation and acylation sites; these modifications contribute to 
multiple band formation of overexpressed WNTs, when they are run on an immunoblot. 
Glycosylation events are primarily at asparagine residues, and are suggested to preceded 
palmitoylation events (Komekado et al., 2007). Perhaps the best-described modification 
of WNTs is the palmitoylation of various cysteine and serine residue by the ER protein 
PORCUPINE (PORCN) (Willert et al., 2003; Takada et al., 2006). These modifications 
are crucial for the recognition of WNTs by WNTLESS (WLS), a sorting receptor that sits 
at the golgi membrane and transports WNTs to the plasma membrane (Bänziger et al., 
2006). Mutations in Porcupine in mice lead to embryonic lethality (Barrott et al., 2011; 
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Biechele et al., 2011), whereas mutations in human PORCN (an X-linked gene), can lead 
to lethality in males and focal dermal hypoplasia in females (Grzeschik et al., 2007; 
Wang et al., 2007). These findings suggest the necessity of palmitoylation of WNTs, in 
order for proper secretion and signaling functions.  
Considering the high levels of lipidation amongst WNTs, it was proposed that 
these proteins were highly hydrophobic. Indeed the hydrophobic nature of WNTs eluded 
researchers in the ability to purify the protein, for over 30 years. The first purification 
was of the murine WNT3A in 2003 (Willert et al., 2003), while the first structure of 
WNT  (Wnt8 in Xenopus) was not solved until 2012 (Janda et al., 2012). The 
hydrophobic nature of WNTs would suggest its poor ability to diffuse across long 
distances extraceullarly. Primarily, WNTs act as morphogens that generate a gradient, 
and act as paracrine cellular signals in a concentration dependent manner. Often times, 
WNTs act across very short distances, such as across the neuromuscular junction or 
within a given stem cell niche (Korkut et al., 2009; Sato et al., 2004). Long-range 
functions of WNTs have recently been proposed to involve either binding with other 
interacting proteins or through transport via exosomes (Mulligan et al., 2011; Gross et al., 
2012).   
Classically, WNT signaling is separated into a canonical and non-canonical 
pathway. Canonical WNTs usually include WNT1, WNT3A, and WNT8, and the classic 
non-canonical WNT is WNT5A. Yet, depending on cellular context and available 
receptors, many WNTs can feed into either pathway (Grumolato et al., 2010). Canonical 
WNT signaling is best described by its ability to induce nuclear localization of B-
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CATENIN and activation of its downstream target genes. Non-canonical WNT signaling, 
on the other hand, is more diverse and can act antagonistically to canonical WNT 
signaling. It is divided primarily into three categories: the planar cell polarity (PCP), 
WNT/Ca2+ and JNK pathways (Gómez-Orte et al., 2013). The PCP pathway regulates 
cellular polarity during morphogenesis, and is involved in such processes as gastrulation 
and neural tube closure. It utilizes mainly the FRIZZLED (FZ) receptors in order to 
activate downstream RHOA and JNK effectors (Schambony and Wedlich, 2007; Minami 
et al., 2010).  In addition to developmental roles, the WNT/Ca2+ pathway can also play a 
role in cancer, inflammation, and neurodegeneration (De, 2011). Its main effector is the 
activation of phospholipase C, which triggers intracellular calcium release, in order to 
activate downstream kinases and phosphatases ultimately toward an N-FAT driven 
transcriptional response (Gómez-Orte et al., 2013). The JNK pathway can utilizes ROR2 
receptors to induce JUN and ATF2 target genes (Schambony and Wedlich, 2007). 
Depending on the WNT, the cell type, and/or the receptor complement, different WNT 
signaling pathways can be elicited, suggesting high diversity and specificity of each 
context. 
The canonical WNT pathway is perhaps the better studied of the two pathways. 
Many of the proteins were elucidated through genetic screens and epistasis experiments 
in Drosophila, in order to determine the order of the pathway components (Sharma and 
Chopra, 1976; Nüsslein-Volhard and Wieschaus, 1980). Canonical WNT signaling is 
initiated with the binding of WNT to the FZ family of receptors and the homologue of 
Drosophila Arrow, low-density lipoprotein (LDL) receptor-related protein (LRP). In 
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addition to WNTs, the FZ/LRP5/6 receptors can also bind to WNT antagonists, such as 
DICKKOPF (DKK), in order to disrupt WNT binding (Semënov et al., 2008). Other 
inhibitors of WNTs include the secreted Frizzled-related proteins (sFRPs) and WNT 
inhibitory protein (WIF), which can sequester away functional WNTs (Bovolenta et al., 
2008). Nevertheless, binding of WNT to its heteromeric receptor complex leads to the 
recruitment of DISHEVELED (DVL) to the FZ receptor, and phosphorylation of the LRP 
tail by CK1α and GSK3 (Tamai et al., 2004). These coordinated events lead to the 
binding of AXIN to the cytoplasmic tail of LRP5/6 (Mao et al., 2001). AXIN is large 
scaffolding complex that houses the destruction complex of B-CATENIN, which include 
adenomatous polyposis coli (APC) and the kinases CK1α and GSK3. Relocalization of 
AXIN to the LRP tail leads to the inhibition of B-CATENIN phosphorylation by 
CK1alpha and GSK3, preventing its degradation (Kishida et al., 1998). The build-up of 
B-CATENIN induces its nuclear translocation, where it can act with Lymphoid 
Enhancer-Binding Factor 1/T cell-specific Transcription Factor (TCF/LEF) binding 
partners to induce transcription of target genes (Aberle et al., 1997).  
WNTs in development  
	  
The diversity in number of WNTs and their high conservation suggest their 
criticalness in multicellular organisms, especially in embryogenesis. One of the first 
studies to demonstrate the importance of WNTs in development utilized ectopic 
overexpression of a murine Wnt1 mRNA in Xenopus laevis blastomeres at the ventral 
end, in order to induce a duplicated dorsal axis (Mcmahon and Moon, 1999). This 
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experiment demonstrates the role of WNT signaling in development patterning and 
additionally highlights the importance of the temporal and spatial restriction of WNTs.  
Over the years, WNTs have been described in a variety of processes in development and 
homeostasis including: proliferation, cell fate specification and differentiation, cellular 
migration, cell adhesion regulation as well as stem cell maintenance, amongst others. 
Wingless, the WNT1 orthologue in Drosophila, in addition to mediating proper 
segmental patterning in embryonic and larvae stages, is critical for the proliferation of the 
wing discs; as its namesake suggests, mutants are wingless (Giraldez and Cohen, 2003). 
Additionally, canonical WNT signaling target genes include MYC and CCND1 in colon 
cancer cells (He et al., 1998; Shtutman et al., 1999), implicating a role of WNT signaling 
in proliferation in specific cellular contexts.  
 Knockout models in mice validated additional roles of WNTs and their signaling 
pathways in embryogenesis. Almost every murine WNT molecule has been knocked out 
either alone or as a double knockout with other WNTs. Many of these knockout mice are 
embryonic or perinatal lethal due to the developmental defects. Herein, I provide a few 
examples to demonstrate the varied tissue types affected by WNTs. WNT1 knockout mice 
do not form midbrains and suffer from ataxia when viable, but succumb shortly after 
birth (Thomas and Capecchi, 1990; Mcmahon and Bradleyt, 1990). Similarly, the 
WNT1/WNT3 compound knockout mice are embryonic lethal by E.18.5 with reduced 
numbers of neural crest precursors (Ikeya et al., 1997), suggesting that WNT1 and 
WNT3A may have redundant roles in induction of proliferation. WNT2 is expressed 
embryonically at the mesenchymal component of the ventral foregut, and when knocked 
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out in mice, leads to embryonic lethality due to lung hypoplasia and reduction of NKX2.1 
expression (Goss et al., 2009). This phenotype is exacerbated with concomitant knockout 
of WNT2B and is also observed in WNT7B null mice (Goss et al., 2009; Shu et al., 2002). 
WNT10B knockout mice, interestingly, develop normally, potentially due to 
compensation by the expression of WNT7B. With aging, WNT10B null mice do exhibit a 
decrease in bone density (Stevens et al., 2010). Additionally, WNT10B null myoblasts 
displayed increased capability to form adipocytes, consistent with previous described 
work, demonstrating WNT10B’s role in inhibiting adipogenic differentiation (Ross et al., 
2000; Cawthorn et al., 2012) (Ross 2000). WNT10B mutation concurrently has been 
shown to be associated with a propensity for obesity in humans (Christodoulides et al., 
2006).   
The WNT10A knockout mouse has not been fully described, but functional aspects 
of WNT10A in development can be surmised by its mutation in human disease. WNT10A 
is one of the primary genes mutated in odontyl-onychol dermal dysplasia (OODD) and 
Schopf-Schulz-Passarge syndrome (SSPS), which are both characterized by a variety of 
ectodermal dysplasias, affecting the hair, teeth, nail, skin, and tongue (Cluzeau et al., 
2011). Prominent phenotypes of individuals with WNT10A missense and nonsense 
mutations include smooth tongues, barrel shaped teeth, and palmar plantar keratoderma 
(Tziotzios et al., 2014). These phenotypes suggest a role of WNT10A in proliferation and 
differentiation of the ectodermal layer of these tissue types. Localization studies of 
Wnt10a expression in the embryonic mouse show that Wnt10a predominates at the 
surface ectoderm, and more specifically in epithelial cells of the anterior apical 
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ectodermal ridge (AER) (Summerhurst et al., 2008).  Wnt10a expression has additionally 
been implicated during hair follicle morophogenesis. The proliferation and downward 
growth of the hair follicle placode is a well-orchestrated process involving careful 
communication between the epithelial and mesenchymal layers.  During embryonic day 
(E) 14.5 of mouse, Wnt10a is expressed throughout the epidermis of the skin, but during 
the start of the hair follicle growth cycle, at E18.5, its expression condenses in the highly 
proliferative hair follicle placode. As hair follicle morphogenesis progresses, Wnt10a 
expression relocates to the inner root sheath. During adult homeostasis, Wnt10a’s 
expression pattern is similar to its embryonic counterpart. Its expression condenses at the 
dermal papilla during the start of anagen (growth phase in hair follicle) and then inhabits 
the inner root sheet during anagen before it is shut off during telogen (rest phase) (Reddy 
et al., 2001). Our own work demonstrates that in addition to ectodermal surfaces of 
mouse embryo and the growth stages of adult hair follicles, WNT10A is highly localized 
to the E14.5 esophagus, during stratification induction by SOX2 and TP63 activity. 
Interestingly, no esophageal phenotypes have been reported in patients with WNT10A 
mutation, suggesting potential redundant roles of other WNTs during esophageal 
development and homeostasis. 
WNT pathway in cancer 
	  
Considering the varied functions of WNTs in development, it is unsurprising that 
WNT signaling can also contribute to disease. Many diseases and developmental defects 
have been alluded to previously. The primary focus of this next section will be to 
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describe the varied roles of WNTs and members of its pathway in cancer. Of note, while 
in many cases, upregulation of canonical WNT signaling can lead to increased 
proliferation, there are exceptions, in which active WNT signaling may be associated 
with improved survival in human cancers (Anastas and Moon, 2013). APC was the first 
described member of the WNT pathway to demonstrate an association with human 
cancer. Based on its namesake, germline APC mutations were frequently seen in patients 
with a hereditary cancer predisposition syndrome, familial adenomatous polyposis (FAP), 
which largely affects the large intestines (Kinzler et al., 1991; Nishisho et al., 1991). 
These mutations would lead to truncation of APC, and its inability to mediate binding of 
the B-CATENIN destruction complex (Groden et al., 1991). APC is also incidentally 
mutated in 84% of all sporadic colorectal cancer cases (Ashton-Rickardt et al., 1989).  
In addition to APC, many other components of the B-CATENIN destruction 
complex are frequently mutated in human cancer. Truncation of AXIN or missense 
mutations in the X-chromosome linked Wilms tumor (WTX) gene, both lead to 
destabilization of the B-CATENIN destruction complex (Salahshor and Woodgett, 2005; 
Major et al., 2007). AXIN mutations are frequently seen in hepatocellular carcinoma, 
where as WTX is oftentimes mutated in Wilms tumor, a pediatric kidney cancer (Satoh et 
al., 2000; Rivera et al., 2007).  Mutations in CTNNB1 itself, specifically at 
phosphorylation sites in the N-terminal, inhibit its ability to be ubiquitinated and 
destroyed. Although these mutations occur in only 1% of colorectal cancer cases, they are 
more frequently seen in other cancers such as medulloblastoma, hepatocellular 
carcinoma, as well as Wilms tumors (Koesters et al., 1999; Polakis, 2007).   
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WNT receptors and inhibitors can also be dysregulated in human cancers. 
Receptor upregulation can lead to activation of canonical WNT signaling. FZ7 is 
frequently upregulated in triple-negative breast cancer; coincidentally in vitro assays 
indicate that its knockdown in both triple-negative breast cancer and hepatocellular 
cancer cells can lead to reduction of xenograft tumor growth (Yang et al., 2011; Wei et 
al., 2011). Truncation mutations in LRP5 are prevalent in parathyroid cancer and 
associate with reduced proliferation and increased B-CATENIN activity in xenograft 
models and cell culture (Björklund et al., 2007). LRP5 is additionally a candidate gene of 
the frequently amplified site 11p13.2 in esophageal cancer (Shi et al., 2014). As 
previously mentioned, sFRPs can bind to FZ receptors to block the transmission of WNT 
signaling. In cancers such as colorectal, medulloblastoma and pancreatic adenocarcinoma 
sFRP1 is hypermethylated, and down-regulated (Suzuki et al., 2004; Vincent et al., 2011; 
Kongkham et al., 2010).   
Finally, overexpression of WNTs themselves is commonly seen in many human 
cancers. Similar to murine mammary tumors, human breast cancer is also associated with 
increase expression of WNT1 (Wong et al., 2002). Interestingly, WNT2 was shown to be 
highly expressed in esophageal cancer, specifically within the tumor-associated 
fibroblasts. Secreted WNT2 was shown to promote proliferation and migratory ability of 
the epithelial cells in cell culture (Fu et al., 2011). WNT5A, on the other hand, can play a 
more complicated role in cancer. In some cases, WNT5A can act as a tumor suppressor, 
and its expression can inhibit proliferation, migration and invasiveness in thyroid tumor 
and colorectal cancer cell lines (Kremenevskaja et al., 2005). In gastric cancer though, 
	  
	  
25	  
WNT5A was shown to promote cell migration by induction of the focal adhesion kinase 
(FAK); its upregulation is additionally associated with poorer prognosis (Kurayoshi et al., 
2006).   
The role of WNT10A in cancer has also been briefly touched up in the recent 
literature. While it has not be classified as a canonical or non-canonical WNT, based on 
homology to WNT10B, which has been confirmed to be a canonical WNT, and based on 
its expression pattern in hair follicle morphogenesis, in relation to induction of nuclear B-
CATENIN, it is highly suggested to act as canonical WNT. The first suggestion of 
WNT10A playing a role in cancer, occurred in 2001, when it was published that WNT10A 
mRNA expression levels were upregulated in a variety of gastrointestinal cancer cell 
lines, including several esophageal cancer cell lines (Kirikoshi et al., 2001a). 
Upregulation of WNT10A is also seen in chronic lymphocytic leukemia, as compared to 
normal B-cells (Lu et al., 2004). Conflictingly, WNT10A has been shown to be 
downregulated in a mesenchymal population of oral squamous cell carcinoma cells, via 
DNA hypermethylation at a nearby CpG island (Kurasawa et al., 2012). In these previous 
reports, WNT10A has only been shown to be correlative with certain cancer types, 
without specificity to mechanism. In renal cell carcinoma, however, WNT10A was 
determined to play a definitive role in enhancing proliferation, migration, invasion and 
chemoresistance, through its induction of active Β-CATENIN. WNT10A expression is 
also associated with poorer survival, especially in concert with high nuclear Β-CATENIN 
and CYCLIND1 staining (Hsu, 2012). We will present data demonstrating the 
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relationship between WNT10A and ESCC, as well as its functions in tumorigenic 
properties (Figure 1).  
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Figure 1 
 
Figure 1. Molecular mechanisms of esophageal cancer. Model demonstrating that 
mutant TP53 (R175/2H) can drive tumorigenesis and invasion both in vitro and in vivo. 
Through a mutant TP53-driven mouse model of ESCC, we demonstrate that mutant TP53 
can promote an epithelial to mesenchymal gene signature. Additionally, in both models, 
we demonstrate the upregulation of WNT10A, which can promote proliferation, 
migration, invasion and stemness properties in vitro.  
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CHAPTER 2: WNT10A promotes an invasive and self-renewing phenotype in 
esophageal squamous cell carcinoma 
	  
The data in chapter 2 have been published in Carcinogenesis.  
Long A, et al., 2015. Carcinogenesis Apr 23; 36 (5); 598-606 
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Abstract 
Esophageal cells overexpressing Epidermal Growth Factor Receptor (EGFR) and 
TP53 mutation can invade into the extracellular matrix when grown in 3D organotypic 
cultures (OTC) and mimic early invasion in esophageal squamous cell carcinoma 
(ESCC). We have performed laser capture microdissection with RNA microarray 
analysis on the invasive and non-invasive tumor cells of TP53R175H overexpressing OTC 
samples to determine candidate genes facilitating tumor invasion. WNT10A was found to 
be >4-fold upregulated in the invasive front. Since WNT10A is also prominently 
upregulated during placode promotion in hair follicle development, a process that 
requires epithelial cells to thicken and elongate, in order to allow downward growth, we 
hypothesized that WNT10A may be important in mediating a similar mechanism of 
tumor cell invasion in ESCC. We have found that WNT10A expression is significantly 
upregulated in human ESCC, when compared with normal adjacent tissue. Furthermore, 
high WNT10A expression levels correlate with poor survival. Interestingly, we observe 
that WNT10A is expressed early in embryogenesis, but is reduced dramatically 
postnatally. We demonstrate that overexpression of WNT10A promotes migration and 
invasion, and proliferation of transformed esophageal cells. Lastly, we show 
that WNT10A overexpression induces a greater CD44High /CD24Low population, which are 
putative markers of cancer stem cells, and increases self-renewal capability. Taken 
together, we propose that WNT10A acts as an oncofetal factor that is highly expressed 
and may promote proper development of the esophagus. During tumorigenesis, it is 
aberrantly overexpressed in order to promote ESCC migration and invasion, and may be 
linked to self-renewal of a subset of ESCC cells.  
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Introduction  
Esophageal squamous cell carcinoma (ESCC) is the sixth leading cause of cancer-
related death amongst American men, and sixth overall cause worldwide (Altekruse SF, 
et al., 2009). Common genetic alterations of ESCC include overexpression of Epidermal 
Growth Factor Receptor (EGFR) and CYCLIND1, as well as mutation in TP53 and either 
loss or mislocalization of p120 CATENIN (Enzinger and Mayer, 2003; Lu et al., 2003; 
Song et al., 2014; Stairs et al., 2011). A recent genome sequencing effort from a cohort of 
158 Chinese ESCC samples revealed that WNT and NOTCH signaling pathways are also 
highly deregulated (Song et al., 2014).  
We have shown previously that overexpression of mutant TP53 (R175H) along 
with EGFR in primary immortalized esophageal epithelial cells induces transformation 
(Okawa et al., 2007). Furthermore, when these engineered cells were grown in 3D 
organotypic culture (OTC), which mimics the stratified epithelium and its crosstalk with 
the underlying stroma, they invade into surrounding stroma, similar to early invasion 
observed in ESCC (Okawa et al., 2007).To understand what molecular mechanisms may 
be responsible for invasion, we dissected out the invasive and non-invasive regions from 
these 3D cultures and performed comparative microarray analysis (Michaylira et al., 
2010). PERIOSTIN, was found to be the highest upregulated gene, and has been 
described previously as a potential biomarker for ESCC (Wong et al., 2013b; a). 
Strikingly, we observed additional dysregulation of a variety of Wnt pathway genes, such 
as upregulation of WNT ligands, WNT10A, WNT5B, and downregulation of the WNT 
pathway inhibitor DKK1 (Michaylira et al., 2010). WNT signaling is critical in the 
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embryonic development of different invertebrate and vertebrate organisms. In particular, 
WNT signaling is critical in the regulation of axis patterning, cell fate specification, cell 
proliferation and cell migration during development (Clevers, 2006; Macdonald et al., 
2009). WNT ligands are secreted glycoproteins that are cysteine-rich and comprise a 
short N-terminal signal sequence with a mature segment that has variable length (Willert 
and Nusse, 2012). There are nearly 20 different WNT proteins, the expression of which is 
spatially and temporally regulated during development, and maintain homeostasis and 
drive cancers in a context dependent manner (Polakis, 2000; Staal et al., 2008). Mouse 
WNT10A is synthesized as a 417 amino acid precursor that contains a 382 amino acid 
mature region, the latter of which contains two potential glycosylation sites. Mouse, rat 
and human WNT10A are highly conserved and WNT10A’s amino acid sequence is 64% 
identical to WNT10B (Wang and Shackleford, 1996; Kirikoshi et al., 2001b). 
Developmentally, WNT10A is best studied in the context of ectodermal lineages. It is 
studied primarily in the deregulation of ectodermal tissues resulting in a variety of 
disorders classified as: odonto-onychal dermal dysplasia (Adaimy et al., 2007; Bohring et 
al., 2009). Manifestation of WNT10A mutations in humans can result in defects in 
dentinogenesis, tooth morphogenesis, odontoblast differentiation, hair follicle 
development, nail formation, papillae of the tongue and sweat gland, and regeneration of 
the epidermis (Bohring et al., 2009; Nawaz et al., 2009; Cluzeau et al., 2011). 
Contributing to this developmental phenotype, WNT10A messenger RNA has been 
shown to strongly localize to the dermal condensates during the earliest stages of 
embryonic hair follicle formation and postnatal anagen (Reddy et al., 2001). This process 
requires coordinated cross-talk between epithelial cells and underlying dermal cells in 
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order to facilitate elongated epithelial cell down growths (Reddy et al., 2001; Itin, 2014). 
Moreover, publically available in situ hybridization data indicates that in addition to 
localization in ectodermal tissues, WNT10A messenger RNA also strongly localizes to the 
embryonic esophagus at embryonic day 14.5, suggesting a role in esophageal 
development (Visel et al., 2004). WNT10A has been previously implicated in a variety of 
cancers and has been shown to promote proliferation, migration and chemoresistance in 
renal cell carcinoma cell lines by regulation of Β-CATENIN (Hsu et al., 2012; Li et al., 
2001; Kirikoshi et al., 2001a; c). Other reports suggest that WNT10A is also upregulated 
in esophageal cancer, gastric and colon cancer cells and tumors (Kirikoshi et al., 2001a). 
By contrast, the WNT10A promoter has been suggested to be hypermethylated in 
head/neck squamous cell carcinoma and oligodendroglioma cell lines (Kurasawa et al., 
2012; Ordway et al., 2006). Herein, we show that WNT10A is upregulated both in early 
development, as well as in early and late stages of ESCC, due its ability to promote 
proliferation, migration, invasion and self-renewal. Taken together, we suggest that 
WNT10A may act as an oncofetal factor in the context of both esophageal development 
and tumorigenesis.  
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Results 
WNT10A is preferentially expressed in the invasive compartment of transformed 
epithelial cells in 3D OTC 
We have identified WNT10A as a prominent upregulated gene in invasive versus 
non-invasive EPC2-hTERT-EGFR-TP53R175H cells grown in 3D OTC, an in vivo like 
model of ESCC (Michaylira et al., 2010). WNT10A was a strong candidate for further 
study, as it was upregulated significantly in the invasive region of another TP53 mutant 
(R248W) (unpublished data). Furthermore, based on pathway analysis of all TP53 
mutants analyzed (R175H, V143A, R248W and R273H), there was a significant 
enrichment for WNT/Β-catenin signaling genes (Figure 1). Interestingly, WNT10A was 
included in other significantly upregulated pathways, such as regulation of epithelial to 
mesenchymal transition and human embryonic stem cell pluoripotency (Supplementary 
Table 1).  
We sought to confirm this expression of WNT10A through immunofluorescent 
staining of 3D OTCs. WNT10A stained predominately in the cytoplasm of epithelial 
cells. Strikingly, we saw stronger staining within the invasive regions (I), as compared 
with the basal non-invasive (NI) regions (Figure 2A). We quantified the mean intensity of 
the staining, and saw that invasive regions had an ~4-fold increase in fluorescent level as 
compared with the basal layer (Figure 2B). We next confirmed that WNT10A expression 
was increased through quantitative PCR. Using a non-invasive cell line, EPC2-hTERT-
EGFR-empty vector cells, we confirmed that the more invasive EPC2-hTERT-EGFR-
TP53R175H cells expressed significantly higher levels of WNT10A messenger RNA 
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(Figure 2C). These results were replicated with several primer sets for WNT10A as 
compared with GAPDH and HPRT (data not shown). 
WNT10A overexpression promotes migration and invasion in transformed 
esophageal keratinocytes 
 Since WNT10A was upregulated in the invasive front of transformed esophageal 
cells grown in 3D OTC, we next wanted to determine the role of WNT10A in mediating 
migration and invasion. To test this hypothesis, we first generated EPC2- hTERT-EGFR-
R175H cells that either overexpressed WNT10A or an empty vector control (herein 
known as WNT10A and empty vector, respectively). We confirmed WNT10A expression 
by western blot (Figure 3A). Several bands were visualized for WNT10A, indicative of 
posttranslational modifications, such as glycosylation and lipidataion, mainly at the 40 
and the 50 kD molecular masses (Willert and Nusse, 2012). Interestingly, overexpression 
of WNT10A resulted in a slight increase in β-catenin protein (Figure 3A), suggesting 
increased stabilization of total β-catenin. WNT10A overexpressing cells exhibited 
increased migratory and invasive capability, as compared with empty vector controls in 
Boyden chamber assays (Figure 3B and C). WNT10A cells exhibited also a significant 
increase in proliferative ability (Figure 3D). 
WNT10A promotes a self-renewal phenotype 
 Based upon our microarray results, WNT10A was suggested to be important in a 
category of genes that promote stem cell pluoripotency, along with genes such as WNT5B 
and SOX2. We therefore wanted to investigate the role of WNT10A in stemness marker 
expression, as well as its ability to promote self-renewal through single sphere assays. 
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CD44, a cell surface marker for hyaluronic acid, has been previously implicated as a 
putative stem cell marker in ESCC, and has been suggested to be regulated by the 
WNT/Β-catenin signaling pathway (Wielenga et al., 1999; Zhao et al., 2011). 
Additionally, CD44High and CD24Low expressing cells have also been described to 
represent a tumor-initiating population with mesenchymal-like properties (Al-Hajj et al., 
2003; Mani et al., 2008). By fluorescence-activated cell sorting-analysis, WNT10A 
overexpressing cells exhibited a marked increase in CD44High and decrease in CD24Low 
cells (Figure 4A), resulting in a nearly 2-fold increase in CD44High/ CD24Low cells with 
WNT10A overexpression (Figure 4B). We next performed single cell sphere formation 
assays in ultra-low attachment plates in the presence of sphere-promoting media. 
WNT10A overexpressing and empty vector control cells were plated in a single cell 
suspension of 100 cells per well. After 7 days, there was a significant increase in the 
average number of spheres formed per well in the WNT10A overexpressing cells as 
compared with control cells (Figure 4C), although there was no difference in the size of 
the spheres that formed. Together, these data demonstrate that WNT10A increases 
migratory and invasive capabilities and promotes a shift toward CD44High cells as well as 
self-renewal. 
WNT10A expression in esophageal development and ESCC 
WNT10A has been implicated previously to be upregulated during early follicle 
morphogenesis as well as in a variety of other ectodermal tissue types (Reddy et al., 
2001; Narita et al., 2005). WNT10A is rarely expressed in the normal adult mouse 
esophagus. Interestingly though, RNA in situ hybridization data of whole mount embryos 
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suggest that in addition to ectodermal lineages, WNT10A is also expressed in the 
developing esophagus (Visel et al., 2004). To confirm this finding, we conducted 
WNT10A IHC in the esophagus at embryonic days (E) 12.5, 18.5, postnatal day (P) 1 and 
adult tissue. We found that WNT10A is expressed as early as E12.5, but exhibits the 
strongest staining at E18.5 (Figure 5A). Interestingly, by P1, WNT10A staining is mostly 
abrogated, although there may be some residual low levels. In normal adult stages, 
WNT10A is expressed minimally. This expression pattern suggests that WNT10A may 
play a role in the development of the early mouse esophagus. 
 In order to examine WNT10A expression in pre-malignant and malignant stages 
of ESCC, we utilized a mouse model of ESCC. The 4-NQO is a quinolone derivative that 
causes DNA-adduct formation similar to carcinogens in tobacco, leading to oral 
squamous and esophageal dysplastic lesions, similar to that of human head neck 
squamous cell and esophageal carcinomas (Tang et al., 2004). In mice treated with 4-
NQO ad libitum in drinking water, we saw increased hyperplastic and dysplastic lesions 
in the esophagi, with downward growths into the submucosa, consistent with invasive 
cancer, as compared with mice on water (control) (Figure 5B). Interestingly, 4-NQO-
treated mice exhibited greater cytoplasmic WNT10A staining in the esophagi, especially 
in the invasive regions, as compared with control mice (Figure 5B). We additionally 
screened a panel of ESCC cell lines via western blot analysis for expression of WNT10A. 
As compared with immortalized primary epithelial cells (EPC2-hTERT), we saw an 
increase in WNT10A expression in three out of the eight ESCC cell lines screened 
(Figure 5C), namely TE6, TE10 and TE11.  
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In order to determine if WNT10A expression could also serve as a biomarker for 
ESCC prognosis, we utilized a tumor microarray (TMA) of 92 normal-matched ESCC 
tumors and 40 additional tumors, along with 5-year survival data on the patients. IHC 
indicated a faint nuclear pattern in samples from normal esophagus samples, while high-
grade dysplasia and invasive tumors presented with overall stronger cytoplasmic staining 
(Figure 5D). An independent pathologist blinded to patient prognosis status scored the 
TMA for cytoplasmic signal (Cy0, Cy1, Cy2 and Cy3). Interestingly, most normal tissues 
expressed either very low (Cy1) or no (Cy0) staining, whereas tumor tissues were mostly 
scored as Cy2 or Cy3 (Figure 5E). When the tumor samples (n = 132) were stratified for 
5-year survival, there was a decrease in median survival time (MST) between the high 
expressers (Cy2, Cy3) MST = 17.5 months versus the low expressers (Cy0, Cy1) 
MST = 33.5 (Figure 5F). Additionally, there was a significant (P = 0.0322) decrease in 
overall survival in the high expressers, based upon the Gehan–Breslow–Wilcoxon test, 
and was trending (P  = 0.0916), based on Log-rank. Taken together, these findings 
suggest that WNT10A is over-expressed in ESCC tumors and cell lines, as well as in 
early esophageal development in the mouse, and that it may be an important biomarker 
for poor survival in ESCC.   
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Discussion 
WNTs are critical signaling factors, required for the development of numerous 
tissue types, as well as maintenance of homeostasis in regenerative tissues, such as of the 
gastrointestinal tract and the skin. Hence, dysregulation of the WNT signaling cascade 
leads to a variety of cancers and diseases. Herein, we have demonstrated WNT10A to be 
expressed in mouse esophageal development, peaking at embryonic day 18.5 but 
diminished substantially postnatally. It is further re-expressed during esophageal 
carcinogenesis as observed in both a mouse model of esophageal epithelial dysplasia as 
well as in human ESCC. These findings suggest that WNT10A may serve as an oncofetal 
factor in the esophagus.  
Interestingly, WNT10A embryonic expression has been described in another 
context of esophageal development. Notably, FOXA3Cre;Cdx2 conditional knockout 
mice, which exhibit esophagealization of the intestine, express increased levels of 
WNT10A in both the mutant intestines, as well as the embryonic esophagus, as these 
mice are embryonic lethal (Gao et al., 2009). In conjunction with our data, these findings 
would lend credence to the premise that differentiation of the esophagus during late 
development may involve WNT10A. SOX2 is a critical transcription factor, also highly 
expressed in embryonic development of the esophagus. It is vital in the division of the 
trachea and the esophagus, in order to promote a single esophageal tube, as well as 
fostering the stratified squamous epithelium within the esophagus (Que et al., 2007). In 
adult life, SOX2 is limited to the basal compartment of esophageal epithelial cells, where 
it promotes proliferation and differentiation (Que et al., 2007). In other squamous 
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epithelial types, both SOX2 and WNT10A have been shown to be important in normal 
development. Interestingly, Sox2 hypomorphic mice and humans carrying WNT10A 
mutation both present with malformation of the fungiform papillae, and ultimately 
smooth tongues, as WNT signaling has been shown to drive SOX2 expression (Adaimy 
et al., 2007; Okubo et al., 2006). These observations suggest a potential connection 
between WNT10A driving SOX2 expression in esophageal development. Indeed, SOX2 
is amplified in ESCC (Bass et al., 2009), and it would be interesting to determine to what 
extent WNT10A and SOX2 are overexpressed concurrently in ESCC.  
Employing a 3D OTC model of ESCC, we found that WNT10A is upregulated in 
the invasive front compared with the non-invasive epithelium. We further demonstrate 
that overexpression of WNT10A enhances esophageal cells ability to proliferate, migrate 
and invade. Loss of function or germline mutation of WNT10A specifically leads to 
malformation of ectodermal appendages during development. These developmental 
processes require careful communication between epithelial and mesenchymal lineages, 
for proper migration of epithelial cells to form placodes and eventually ectodermal tissues 
(Itin, 2014). Specifically, during the hair follicle development, and then later in anagen, a 
period of growth during the hair follicle cycle, WNT10A is upregulated near the dermal 
condensate and later dermal root sheet, and may be required for the downward growth of 
the hair follicle (Reddy et al., 2001). Therefore, we propose that WNT10A may be 
normally required for epithelial migration and proliferation during development, and that 
the oncogenic state is co-opting a developmental process to facilitate carcinogenesis. This 
pattern is frequently seen in the context of other oncofetal factors.  
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We also observe that WNT10A expression is also increased in an ESCC TMA 
when compared with adjacent normal esophagus, and correlates with decreased MST. 
Patients with ESCC that express higher WNT10A levels had an overall significant 
decrease in 5-year survival time, as well. These data suggest that WNT10A can annotate 
the invasive compartment of ESCC and could potentially be used as a biomarker for 
poorer prognosis in ESCC. Similarly, WNT10A has been shown to be upregulated in 
renal cell carcinoma biopsies and drives proliferation, migration and chemoresistance of 
renal carcinoma cell lines (Hsu et al., 2012). Taken together, these data suggest that 
WNT10A can act as an oncogene in a variety of tissue types.  
We additionally demonstrated that WNT10A could induce stem cell-like 
properties by promoting self-renewal. These data are supported by our pathway analysis 
of invasive mutant TP53 cells, which suggests that in addition to epithelial to 
mesenchymal transition, WNT10A may also play a role in maintaining embryonic stem 
cells. Indeed, WNT10A is secreted by mammary stem cells and it may be required for 
maintaining this population (Ji et al., 2011). Wnt signaling is also required for the 
maintenance of a variety of stem cell niches, such as in intestinal crypts and 
hematopoietic systems (Korinek et al., 1998; Reya et al., 2003). Interestingly, we have 
demonstrated previously that PERIOSTIN, a type of matricellular protein involved in 
remodelling the tumor stroma during tumor cell invasion, is upregulated in ESCC, 
mediates ESCC invasion and is critical in tumorigenesis in vivo (Michaylira et al., 2010; 
Wong et al., 2013b; a; Wong and Rustgi, 2013). Indeed, metastatic tumor cells induce 
stromal PERIOSTIN expression in the secondary target organ (e.g. lung) to initiate 
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colonization (Malanchi et al., 2012; Holland et al., 2013). PERIOSTIN is needed for 
cancer stem cell maintenance and recruits WNT ligands for increased WNT signaling in 
cancer stem cells (Malanchi et al., 2012). Whether PERIOSTIN and WNT10A interact in 
this context is an area for future investigation.  
Our study is the first report to demonstrate a role for WNT10A in both esophageal 
development and in tumorigenesis. Our data suggest that in a TP53 mutant background, 
WNT10A mediates tumor cell migration and invasion, while increasing a population of 
self-renewing CD44High cells. Interestingly, up to 83% of ESCC cases exhibit mutant in 
TP53, while altered genes in the WNT pathway represent almost 85% cases of ESCC 
(Song et al., 2014). These mutations may work synergistically to promote more 
aggressive and invasive tumors in ESCC. 
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Materials and methods  
Network analysis  
Ingenuity Pathway Analysis was used to identify potential upstream regulators 
that control gene expression patterns enriched in invasive TP53 mutant cell lines. The 
analysis is based on prior knowledge of expected effects between transcriptional factors 
and their target genes stored in the Ingenuity Knowledge Base (Krämer et al., 2014). 
Briefly, the analysis examines the known targets of each transcription factor in the 
signature and compares their direction of change (expression in invasive relative to the 
non-invasive gene signature) to what is expected from the literature. If the direction of 
change is consistent with the literature across the majority of targets, then the regulator is 
predicted to be active in invasive cells, whereas if the direction of change is mostly 
inconsistent (anti-correlated) with the literature, then the regulator is predicted to be 
inactive in invasive cells. Regulation z-score was used to estimate the activation state of 
the regulators. The overlap P values generated by Fisher’s exact test were used to 
estimate the statistical significance of overlap between the dataset genes and the genes 
regulated by a regulator.  
Cell culture  
EPC2-hTERT cells and derivatives, established and extensively characterized by 
us, were grown in keratinocyte serum-free media (Invitrogen, Carlsbad, CA), 
supplemented with 40  µg/ml of bovine pituitary extract, 1ng/ml epidermal growth factor 
and 1% penicillin/streptomycin, as described previously (6,7,32). The TE series human 
ESCC cells were a gift from Dr. Nishihira who established the cell lines and were grown 
in Dulbecco's modified Eagle's medium supplemented by 10% fetal calf serum (Sigma–
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Aldrich, St. Louis, MO) and 1% penicillin/streptomycin (Invitrogen) as described 
previously (Nishihira et al., 1993; Nakagawa et al., 1995). The earliest frozen stocks of 
all cell lines have been stored at the Cell Culture Core of the University of Pennsylvania. 
We have propagated cells from frozen stocks of the original vials that were authenticated 
by short tandem repeat analysis for highly polymorphic microsatellites FES/FPS, 
vWA31, D22S417, D10S526 and D5S592 as performed by the Cell Culture Core to 
validate the identity of cells by comparing cells at the earliest stocks we have and those 
grown >8–12 passages. All cell lines have been tested for mycoplasma contamination on 
a regular basis. WNT10A was a gift from Marian Waterman (Addgene plasmid # 35920), 
and was subcloned into pBabe-Blast empty vector (Najdi et al., 2012). Retroviral 
spinfection was performed as described previously (Michaylira et al., 2010). 3D OTCs 
Epithelial cells were grown as described (Kalabis et al., 2012), in order to recreate the 
microenvironement of ESCC, by supplying extracellular membrane components, 
including collagen and fetal esophageal fibroblasts. 
 Mouse treatments  
4-nitroquinoline 1-oxide (4-NQO) experiments were performed as described 
previously and under Institutional Animal Care and Use Committee (IACUC) approval 
(Tang et al., 2004). In brief, 6-week-old C57Bl/6 and mixed background mice were given 
10mg/ml of 4-NQO diluted in 10% propylene glycol in their drinking water ad libitum. 
Mice were randomized amongst littermates into control versus treatment groups. Mice 
were euthanized either directly after treatment or after a 12-week wash out period. Three 
to five mice, per condition, were euthanized and tissues were processed for histology and 
IHC.  
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Tumor microarrays and IHC/immunofluorescence  
 ESCC tissue along with adjacent non-cancerous mucosa were obtained as surgical 
biopsies from Kagoshima University Hospital, as described previously (37). The clinical 
materials were obtained from informedconsent patients according to the Institutional 
Review Board standards and guidelines. IHC and immunofluorescence were performed 
as described previously (37). About 5 µM paraffin embedded sections were incubated 
with WNT10A (Ab-106522, Abcam, Cambridge, MA 1:200) or WNT10A (SC-376028, 
Santa Cruz Biotechnologies, Santa Cruz, CA 1:100). Immunofluorescence signal was 
quantified in at least four independent high-powered fields per slide for mean intensity 
using ImageJ (Schneider et al., 2012).  
RNA isolation and quantitative PCR  
Total RNA was isolated using GeneJet RNA Purification Kit (Thermo Fisher 
Scientific, Waltham, MA) and cDNA was synthesized utilizing the Taqman Reverse 
Transcription Reagents kit (Applied Biosystems, Foster City, CA) according to the 
manufacturer’s instructions. Quantitative PCR was performed with primer sequences for 
WNT10A Forward: 5′-ATCCACGAATGCCAACACCA-3′, Reverse: 5′-
CTCTCTCGGAAACCTCTGCT-3′ and ACTB Forward: 5′-CCTGGCACCC 
AGGACAAT-3′, Reverse: 5′-GCCGAGCCACACGGAGTACT-3′ using Power SYBR 
Green PCR Master Mix (PE, Applied Biosystems), according to manufacturer’s 
instructions.  
Western blotting  
Proteins were separated through 4–12% sodium dodecyl sulfate–polyacrylamide 
gel electrophoresis Bis-Tris gel (Invitrogen) and then transferred to a poly membrane 
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(Immobilon-P; Millipore, Billerica, MA). Membranes were then blocked with 5% non-fat 
milk in TBS-T (1× TBS and 0.01% Tween-20), probed with primary antibody (1:500 
WNT10A SC-376028, Santa Cruz, 1:1000 β-CATENIN D10A8, Cell Signaling, and 
1:1000 GAPDH, Millipore) diluted in blocking buffer overnight at 4°C, washed with 
TBST-T and incubated with horseradish peroxidase-coupled secondary antibodies (GE 
Healthcare, Pittsburgh, PA). Signal was visualized with Amersham ECL-Prime (GE 
Healthcare) as per manufacturer’s instructions.  
Migration and invasion assays 
Boyden chambers (8-µm pore size, FluoroBlok-HTS inserts; BD Biosciences, San 
Jose, CA) were used for migration and invasion assays, as described previously (6). In 
brief, Boyden chambers were coated with 200 µg/ml of Matrigel Matrix (BD 
Biosciences) 2h before cell plating. Inserts were placed in a 24-well plate containing full 
keratinocyte serum-free medium to stimulate cell migration and invasion. Cells (5×104 ) 
in keratinocyte basal media (Lonza, Basel, Switzerland) were placed in each insert. 
Twenty-four hours later, migrating or invading cells were labeled with 4 µg/ml Calcein 
AM dye (Invitrogen) in Hanks’ buffered salt solution buffer (Invitrogen) for 1h. Labeled 
cells were then read on a Synergy HT multidetection microplate reader (BioTek, 
Winooski, VT) at 485-nm excitation and 528-nm detection. Data represents the average 
of three independent experiments performed in triplicate for each genotype.  
Cell proliferation assay  
A total of 3×103 cells were cultured in 96-well plates. Cell proliferation was 
quantified using the WST-1 colorimetric assay (Roche, Penzberg, Germany) according to 
manufacture’s instructions. Absorbance was measured on a microplate reader (Tecan 
	  
	  
47	  
Sunrise, Männedorf, Switzerland) at a wavelength of 450nm. Data represents the average 
of five independent experiments performed in quintuplicate.  
Flow cytometry and fluorescence-activated cell sorting  
Flow cytometry was performed using LSRII (BD Biosciences) and FlowJo (Tree 
Star, Ashland, OR). Cells were suspended in phosphate-buffered saline (Invitrogen) 
containing 1% BSA (Sigma–Aldrich) and stained with PE/Cy7-anti-CD24 (1:40; 
BioLegend, San Diego, CA) and APC-anti-CD44 (1:20; BD Biosciences) on ice for 
30min. Flow cytometry data represent at least three independent experiments.  
Self-renewal assays  
About 100 cells were plated in single suspension in an ultra-low attachment 96 
well-plate in 100 µl of mammary epithelial cell growth medium (Invitrogen). After 
7 days, spheres were visualized and counted. All spheres consisted of greater than three 
cells. Data represents three independent experiments performed in 96 replicates for each 
cell type.  
Statistics  
 Each experiment is presented as mean ± standard error (at least n=3) and was 
analyzed by paired or non-paried two-tailed Student’s t-test. P < 0.05 was considered 
significant. Overall survival curves were plotted by the Kaplan-Meier method and 
subjected to the Log-rank and Gehan-Wilcoxon test. Chi-square test was used to 
determine differences in proportion of WNT10A scoring in normal versus tumor samples.  
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Figures and figure legends 
  
	  
	  
49	  
Figure 1 
 
 
Figure 1. WNT pathway is significantly upregulated in invasive mutant TP53 cells. 
Ingenuity Pathway analysis shows networks of genes, known to be regulated by WNT 
signaling in gene expression data, are significantly associated with TP53 mutations. 
Upregulated and downregulated genes are indicated by red and green, respectively. The 
lines and arrows represent functional and physical interactions and the directions of 
regulation, as indicated in the literature.  
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Figure 2
Figure 2. WNT10A is upregulated in invasive esophageal cells. (A) Representative 
Hematoxylin and Eosin (H&E), WNT10A and DAPI staining of EPC2-hTERT-EGFR-
TP53R175H  cells grown in 3-D organotypic culture (OTC). Non-invasive (NI) and 
invasive (I) regions are delineated by white dots (B) Quantification utilizing ImageJ for 
mean fluorescent intensity of WNT10A staining in the non-invasive versus invasive front 
(n=4 independent experiments). Fluorescent intensity of invasive front is relative to non-
invasive regions. Bar graphs represent relative mean ± SEM. **p<.005 (paired student’s 
t-test) (C) qRT-PCR of WNT10A expression relative to ACTB comparing non-invasive 
EPC2-hTERT-EGFR cells versus invasive EPC2-hTERT-EGFR-TP53R175H cells (n=3 
experiments). Bar graph represents fold change ± SEM. **p<.005 (unpaired student’s t-
test). 
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Figure 3 
Figure 3. WNT10A promotes migration and invasion. (A) Western blot (cropped 
image) of EPC2-hTERT-EGFR-p53R175H either overexpressing empty vector or 
WNT10A. Multiple bands indicate post-translational modifications of WNT10A. B-
catenin densitometry indicates a modest 1.3-fold increase in total β-catenin relative to 
GAPDH, with WNT10A overexpression (n=3 experiments). (B) Transwell Boyden 
Chamber migration assay of Empty Vector compared to WNT10A cells along with 
representative images of migratory cells stained with Calcein AM. (C) Transwell Boyden 
Chamber invasion assay of Empty Vector compared to WNT10A cells with 
representative images of invasive cells stained with Calcein AM. Scale bars =100 µM. 
n=3 in triplicate. Bar graphs represent fold changes ± SEM. *p<.05, **p<.005 (paired 
student’s t-test). (D) Proliferation assay utilizing a WST-1 colorimetric assay. (n= 5 
experiments in quintuplicate). *p<.05 (paired student’s t-test).  
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Figure 4 
 
Fig. 4. WNT10A increases CD44High population and promotes self-renewal. (A) 
Representative histograms of CD44 and CD24 levels between Empty Vector and 
WNT10A cells, as expressed in a logarithmic scale. (B) Quantification of the 
CD44High/CD24Low population between Empty Vector and WNT10A cells (n=3 
experiments). Bar graphs represent fold change ± SEM within 3 different passages of 
cells within one representative experiment. **p<.005 (unpaired student’s t-test). (C) 
Quantification of the average number of spheres formed per well between Empty Vector 
and WNT10A cells (n=3 experiments in 96 replicates). Bar graph represents fold change 
± SEM. *p<.05 (paired student’s t-test). Representative images of the spheres from each 
cell type indicate no difference in the size of the spheres formed. Each image was taken 
at a magnification of x100.   
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Figure 5 
 
 
Figure 5. WNT10A is upregulated during esophageal development and in cancer. 
(A) WNT10A IHC of embryonic (E12.5, E18.5), postnatal day 1 (P1), and adult 
esophagus (E). Epithelial (e) and mesenchyme (m) are as indicated. (B) Representative 
WNT10A staining in esophagus of control mice versus mice treated with 10mg/ml of 4-
NQO for 16 weeks. Downward growths and hyperplasia/dysplasia are indicative of early 
ESCC. Bar graph represents average scoring of esophagi ± SEM. *P < 0.05 (unpaired 
Student’s t-test) of three control and five experimental mice. (C) Western blot  (cropped 
image) for WNT10A on a panel of ESCC human cell lines, as compared to normal, 
immortalized epithelial cells (EPC2-hTERT).   
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Figure 5 
 
 
Figure 5. WNT10A is upregulated during esophageal development and in cancer. 
(D) Representative images of WNT10A scoring classifications of adjacent normal (upper 
left panel) versus carcinoma in situ (CIS), and tumor tissue. Scoring was based on 
cytoplasmic intensity (Cy0, Cy1, Cy2, and Cy3). All scale bars are 100µM. (E) Scoring 
stratified between low staining intensity (Cy0 and Cy1) and high staining intensity (Cy2 
and Cy3) WNT10A staining between normal adjacent tissue and tumor sections, 
respectively (red square box). p<.0001 (Chi-square test).   
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Figure 5 
 
 
Figure 5. WNT10A is upregulated during esophageal development and in cancer. 
(F) Kaplan-Meyer survival curve of tumor staining stratified between low WNT10A 
staining intensity versus high WNT10A staining intensity, with median survival time 
(MST).  
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Tables and table legends 
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Supplementary Table 1:  
Ingenuity Canonical Pathways P-values Molecules 
Cell Cycle Control of Chromosomal Replication 5.88844E-07 CDC7,MCM2,MCM6,MCM4,MCM5,CDC6 
Mitotic Roles of Polo-Like Kinase 1.23027E-05 
CDC7,PRC1,PLK4,CDC20,HSP90AB1,CCNB1,CDC
27 
Regulation of Cellular Mechanics by Calpain 
Protease 0.000549541 CAPN3,CNGB1,TLN1,CCNA2,ACTN1 
VDR/RXR Activation 0.002238721 KLK6,IGFBP3,CALB1,CSNK2A1,IGFBP6 
Cyclins and Cell Cycle Regulation 0.002238721 CCND2,CCNA2,HDAC4,HDAC9,CCNB1 
Role of IL-17A in Arthritis 0.003715352 CCL7,CCL2,PIK3C2B,CXCL5 
IGF-1 Signaling 0.005754399 SOCS3,PIK3C2B,IGFBP3,CSNK2A1,IGFBP6 
p53 Signaling 0.006025596 CCND2,BIRC5,PIK3C2B,ADCK3,HDAC9 
Regulation of the Epithelial-Mesenchymal 
Transition Pathway 0.00616595 
WNT10A,PARD6B,WNT5B,PIK3C2B,EGR1,JAG, 
HGF 
Eicosanoid Signaling 0.006456542 ALOX15B,RARRES3,PLA2G4F,PTGES 
Paxillin Signaling 0.007079458 TLN1,PIK3C2B,ITGB8,PARVA,ACTN1 
IL-17A Signaling in Fibroblasts 0.007943282 CCL7,CCL2,CXCL5 
BER pathway 0.008317638 FEN1,LIG1 
Role of IL-17A in Psoriasis 0.009772372 S100A7,CXCL5 
Integrin Signaling 0.01 
CAPN3,TLN1,PIK3C2B,ITGB8,PARVA,ACTN1,AR
PC1B 
IL-17 Signaling 0.01023293 MMP3,CCL2,PIK3C2B,CXCL5 
Role of IL-17F in Allergic Inflammatory Airway 
Diseases 0.014791084 CCL7,CCL2,CXCL5 
Atherosclerosis Signaling 0.015135612 MMP3,CCL2,ALOX15B,RARRES3,PLA2G4F 
GADD45 Signaling 0.020417379 CCND2,CCNB1 
Human Embryonic Stem Cell Pluripotency 0.020892961 WNT10A,WNT5B,PIK3C2B,SOX2,BDNF 
Insulin Receptor Signaling 0.020892961 PPP1R3D,PPP1R14A,SOCS3,PIK3C2B,GYS2 
L-glutamine Biosynthesis II (tRNA-dependent) 0.023442288 GATB 
Chronic Myeloid Leukemia Signaling 0.023988329 MECOM,PIK3C2B,HDAC4,HDAC9 
CDK5 Signaling 0.029512092 PPP1R3D,PPP1R14A,EGR1,BDNF 
Telomerase Signaling 0.029512092 PIK3C2B,HDAC4,HSP90AB1,HDAC9 
Ascorbate Recycling (Cytosolic) 0.034673685 GLRX 
Glutathione Redox Reactions II 0.034673685 GLRX 
4-aminobutyrate Degradation I 0.034673685 ALDH5A1 
Cell Cycle: G1/S Checkpoint Regulation 0.039810717 CCND2,HDAC4,HDAC9 
Role of NANOG in Mammalian Embryonic Stem 
Cell Pluripotency 0.041686938 WNT10A,WNT5B,PIK3C2B,SOX2 
Role of MAPK Signaling in the Pathogenesis of 
Influenza 0.045708819 CCL2,RARRES3,PLA2G4F 
GDNF Family Ligand-Receptor Interactions 0.045708819 NRTN,PDLIM7,PIK3C2B 
Remodeling of Epithelial Adherens Junctions 0.045708819 ACTN1,HGF,ARPC1B 
Macropinocytosis Signaling 0.045708819 PIK3C2B,ITGB8,HGF 
Hereditary Breast Cancer Signaling 0.046773514 PIK3C2B,HDAC4,HDAC9,CCNB1 
Growth Hormone Signaling 0.047863009 SOCS3,PIK3C2B,IGFBP3 
Wnt/Î²-catenin Signaling 0.048977882 WNT10A,WNT5B,DKK1,SOX2,CSNK2A1 
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Supplementary Table 1. Significantly upregulated pathways associated with 
invasive mutant TP53 gene signature. Upregulated pathways associated with invasive 
TP53 mutant (R175H, R248W, R273H, V143A) gene signature P-values (Fisher’s exact 
test) estimate the statistical significance of the overlap between the dataset genes and 
genes regulated by the regulator. Bolded boxes indicate upregulated pathways associated 
with WNT10A 
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CHAPTER 3: The role of mutant TP53 in the development of a mouse model of 
esophageal squamous cell carcinoma 
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Abstract 
 Wild-type TP53, a potent tumor suppressor gene, is responsible for initiating 
appropriate responses to a variety of cellular stresses and is the most commonly mutated 
gene in human cancers. Strikingly, most TP53 mutations are missense mutations within 
one of six hotspot codons in the DNA-binding domain (DBD). Recent evidence suggests 
that the DBD mutants can confer neomorphic activity or act as gain-of-function (GOF) 
mutants, in order to promote tumor progression. Over 80% of esophageal squamous cell 
carcinomas (ESCC) contain TP53 mutation, with the majority within the DBD. Major 
risk factors of ESCC include smoking, alcohol use, and factors that induce tissue stress, 
such as irradiation and caustic injury of the esophagus. In order to determine how TP53 
mutation affects the progression of ESCC, we developed a mouse model of ESCC, which 
is driven by an esophageal specific Cre-recombinase, in order to induce Tp53 mutation, 
and a chemical mutagen, 4-Nitroquinoline 1-oxide (4NQO). Mice are additionally lineage 
labeled with an YFP+ allele, to allow for detection of recombined cancer cells in 
metastatic sites, such as lymph nodes and lung. We found that mutation in Tp53 (R172H) 
significantly accelerates initiation and progression of ESCC by 4 to 6 weeks, as compared 
to total Tp53 loss. This finding suggests that mutant TP53 can promote tumorigenesis in a 
GOF mechanism. Furthermore, in order to further elucidate the role of Tp53 mutation in 
ESCC, we performed RNA-seq on established cancer cell lines from mouse tumors, with 
or without TP53 mutation or loss. Our preliminary findings suggest mutant TP53 may 
promote an epithelial to mesenchymal transition (EMT) gene signature, leading to a 
potential GOF role of mutant TP53 in ESCC metastases.  
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Introduction 
 Esophageal squamous cell carcinoma (ESCC) is one of the deadliest tumor types 
due to its highly invasive and early infiltrative nature (Altekruse et al., 2009). It is 
characterized by high-grade dysplasia of the epithelial layers with invasion into the 
lamina propria and potential extension into the muscle layers and surrounding tissue, 
depending on tumor grade (Taylor et al., 2013). Major risk factors of certain etiologies of 
ESCC include smoking and alcohol use (Toh et al., 2010). Additionally, it is one of the 
cancers with the highest rate of TP53 mutation, suggesting that TP53 mutation may be a 
driver of carcinogenesis.  
 Our lab has previously described an in vitro role of mutant TP53 in ESCC. When 
primary epithelial immortalized cells overexpress mutant TP53 in conjunction with 
Epidermal Growth Factor Receptor (EGFR) overexpression, they develop enhanced 
proliferative, migratory, invasive and colony formation capabilities (Okawa et al., 2007). 
More specifically, these cells can induce invasion in an in vivo-like system of 3D 
organotyipc culture (OTC), with cellular protrusions into the underlying 
fibroblast/matrigel/collagen support layer (Michaylira et al., 2010; Kalabis et al., 2012). 
Incidentally, different hotspot DNA binding domain (DBD) mutations of TP53 exhibited 
different tumorigenic properties in the cell culture model of esophageal cancer, with the 
conformation-altering mutant R175H being the most invasive (Michaylira et al., 2010). 
These hotspot mutants have previously been suggested to confer gain-of-function (GOF) 
or neomorphic properties to induce additional oncogenic capabilities in cancer cells. 
	  
	  
62	  
In order to better elucidate the mechanisms by which mutant TP53 may be 
promoting ESCC, we chose to generate an in vivo mouse model of ESCC driven by the 
R172H mutation (mouse orthologue of human R175H). Indeed, previous mouse models 
of ESCC have been derived, through other mechanisms, which will be briefly discussed 
below.  
(1) Namely, the fastest and most highly penetrant model of mouse ESCC utilizes 
4-nitroquinoline 1-oxide (4-NQO) in the drinking water. 4-NQO is a carcinogen that can 
induce bulky adducts in DNA, as well as DNA breaks, similar to cigarette smoke. Mice 
are administered 4NQO in their drinking water for an initial 16-week period with an 
additional 12-week wash out period. After the end of the 28-week experimental period, 
mice on 4NQO develop 100% penetrance of hyperplasia, papilloma, and invasive 
carcinoma. A caveat of this model is its stochastic nature, which is purely carcinogen 
driven (Tang et al., 2004). 
(2) Concurrent loss of E-CADHERIN and Transforming Growth Factor Beta-
receptor II (TGFBR2) in vitro has also proven to induce invasion of esophageal cancer 
cells in vitro (Andl et al., 2006). When these genes were deleted in mice with the L2 
promoter driven Cre recombinase (L2-Cre), which is specific for the oral squamous, 
ventral tongue, esophageal, and forestomach, there was development of oral squamous 
cell carcinoma over a period of 18 months. Notably though, these mice also demonstrated 
metastasis in lymph node and lung tissue (Nakagawa et al., 1997; Andl et al., 2014).  
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(3) SOX2 is a driver of proliferation and stratification of the esophageal lineage in 
development (Que et al., 2007). Furthermore, its re-expression has been shown to be 
prominent in various squamous cell cancer types, especially in ESCC. When SOX2 
overexpression is induced by the Keratin 5 (Krt5) promoter, which is specific for the 
basal layer of the epidermis and aerodigestive tract, mice develop carcinomas in the 
forestomach over the period of 5 months.  These carcinomas display increased nuclear 
STAT3 localization, which suggest an inflammatory component requirement in the 
development of carcinoma. Only when SOX2 is overexpressed concomitantly with 
nuclear STAT3, can esophageal carcinoma develop. Limitations of this model include the 
localization of the carcinoma, which is not esophageal specific and the dermatitis 
development in these mice, due to expression of Krt5 in the basal layer of the epidermis, 
as well (Liu et al., 2013).  
(4) Another inflammatory driven model of esophageal cancer utilizes deletion of 
Ctnnb2 (p120 CATENIN). In human ESCC samples, p120 CATENIN has been 
demonstrated to be either lost or mislocalized away from the cell membrane, where it 
would normally tether E-CADHERIN. Interestingly, when p120 CATENIN was deleted 
with the L2-Cre recombinase, not only did E-CADHERIN appreciably decrease but there 
was additionally increased expression of nuclear NF-KAPPAB. Over the course of 8 to 
12 months, these mice developed dysplasia and invasive carcinoma of the oral tissue, 
esophagus and forestomach. Treatment of these mice with dexamethasone, led to a 
decrease in the proliferation and tumor invasion, suggesting that inflammation can also 
drive esophageal carcinogenesis (Stairs et al., 2011).  
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Taken together, we decided to utilize genetic and environmental components, in 
order to generate a model of murine ESCC. We chose a common mutation of TP53 in 
humans, as the R175H mutant accounts for 6% of all TP53 mutations in ESCC and 
utilization of 4-NQO, as it can accelerate the progression of ESCC in mice. Additionally, 
we chose to utilize the L2-Cre recombinase, as it is most specific for esophageal tissue.  
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Results 
Generation of a mouse model of ESCC.  
 We utilized mice that had a knock-in mutation at the R172H codon of Tp53 
(Olive et al., 2004). By crossing these knock-in mutants to mice with a L2-Cre 
recombinase transgene and additional floxed alleles surrounding the Tp53 loci, we were 
able to generate compound Tp53 mutant mice, specifically in the oral squamous, 
esophageal, and forestomach tissues (Nakagawa et al., 1997; Marino et al., 2000). 
Ultimately, we generated five different combinations of genotypes at the Tp53 loci: +/+, 
+/-, R172H/+, -/- , and R172H/-. Additionally, we crossed in at least one copy of the R26-
stop-EYFP allele to each mouse. This allele allows expression of the EYFP gene at the 
Gt(Rosa)26Sor loci when a Cre-recombinase is expressed to delete the lox-p flanked 
STOP sequence, thus allowing lineage labeling of all recombined cells. At 8-12 weeks of 
age, mice were subjected to treatment of 10 mg/mL 4-NQO ad libitum in their drinking 
water for 16 weeks and then euthanized (Figure 1A).  
 Initial histology of the esophagus of these mice showed varying degrees of 
hyperplasia, dysplasia, downward growths, micro invasion, and frank invasive squamous 
cell carcinoma, depending on genotype. In TP53+/+ control mice, the predominant 
features of the esophagi were hyperproliferation of the basal layer and a mild 
inflammatory response (Figure 1B). When one allele of Tp53 was lost, TP53+/- mice 
exhibited increase in basal layer proliferation along with dysplastic features of suprabasal 
layer. Downward growths can also initially be seen (Figure 1C). In TP53R172H/+ mice, 
increased dysplasia and inflammation is seen, with signs of microinvasion into the 
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underlying lamina propria (Figure 1D). TP53-/- mice, herein known as TP53 null mice, 
displayed variability in phenotype between microinvasion and invasive squamous cell 
carcinoma (Figure 1E). Lastly, TP53R172H/- mice, herein known as compound mutants, 
displayed thickened esophagi with macroscopic tumors, causing food impaction (data not 
shown) and invasive squamous cell carcinoma to both the lamina propria and surrounding 
muscle layers (Figures F and G).  
 TP53 immunohistochemistry staining was confirmed in the null mice and the 
compound mutants (Figures 1H-J). No antibody control (Figure 1H) displayed no TP53 
staining, and TP53 null mice exhibited either low levels or no nuclear staining. Positive 
nuclear TP53 staining in the TP53 null histological samples may signify immune 
infiltrates, which maintain two wildtype copies of the Tp53 gene (Figure 1I). Compound 
mutant mice exhibited high levels of TP53 nuclear staining both in the epithelial layer as 
well as underlying stroma and muscle layers, indicative of invasive epithelial cells. TP53 
staining was performed on TP53+/+, TP53+/- and TP53R172H/+ mice and showed 
intermediate levels of nuclear TP53 staining, indicative of either active wildtype or 
mutant TP53, as the two alleles are indistinguishable based on IHC staining (data not 
shown). YFP expression was also confirmed by a fluorescent microscope, as a marker of 
recombination (Figure 1K-L), indicating strongest fluorescence in tumor tissue.   
Mutant TP53 may decrease tumor latency 
 Having established a mutant TP53 driven mouse model of ESCC, but with 
varying histological patterns, we next wanted to determine if there were differences 
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amongst the different genotypes of mice. We additionally wanted to determine if the 
TP53R172H mutation could confer GOF properties over the null allele. In order to examine 
tumor latency, we chose to treat all experimental mice with the same 16 weeks of 4-NQO 
in the drinking water ad libitum but additionally included a washout period. During the 
16-week treatment period as well as the 12-weeks following, we carefully monitored 
mice for signs of distress and significant weight loss (Figure 2A). 
 When mice displayed signs of illness, they were euthanized and examined grossly 
and via histology for invasive squamous cell carcinoma, and we plotted tumor incidence 
at specific time points for each genotype (Figures 2B and 2C). When sick mice were 
euthanized and found not to contain an esophageal tumor, these mice were marked as 
only censored at that particular time point. We firstly compared the tumor incidence 
curves between the TP53R172H/+ and TP53+/- mice, which would allow us to compare the 
effects of a TP53R172H allele versus the null allele when one wildtype copy of Tp53 is till 
present (Figure 2B). In effect, we saw no difference between these two curves in terms of 
tumor incidence. Additionally, the TP53R172H/+ and TP53+/- mice had median tumor 
incidence of 24.5 weeks and 23 weeks respectively. We next compared directly the 
compound mutant mice the null mice. There was a significant difference in terms of their 
tumor incidence curves (Gehan-Breslow-Wilcoxon test p=.0470) (Figure 2C). 
Additionally, the median survival time between both of these groups were shorter 
compared to the TP53R172H/+ and TP53+/- group; the compound mice and null mice had a 
median tumor incidence time of 18 weeks and 22 weeks, respectively. Wildtype mice 
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treated with 4-NQO were also monitored, but these mice did not begin developing tumors 
until 14 to 16 weeks after the washout period begin (Data not shown).  
 Interestingly, during the 12-week washout period, mice of all genotypes began 
developing metastases to adjacent lymph nodes as well as micrometastases to the lungs. 
Lymph nodes were dissected out and examined under the fluorescent microscope and 
determined to be YFP+, indicating epithelial origin (Figure 2D and E). Additionally, 
histologically, dysplastic epithelial cells can be found in the lymph node. Lung tissue also 
showed signs of micrometastases by histology (Figure 2F). These findings suggest that 
TP53 mutation or loss in concert with 4-NQO treatment can induce a metastatic model of 
ESCC in mice.  
Mutant TP53 may confer an epithelial-mesenchymal transition (EMT) signature 
 To further dissect out the GOF role of mutant TP53 in ESCC, we generated cell 
lines from the tumors of both the null and compound mutant mice in order to perform ex 
vivo experiments. In these initial experiments, we were able to generate two different 
TP53 compound mutant cell lines and one null cell line. Cell lines were further confirmed 
to express YFP (Figure 3A), to exclude contaminating, non-esophageal epithelial cells. 
Furthermore, TP53 was shown to be stabilized and highly upregulated in both compound 
mutant cell lines but not expressed in the null cell lines (Figure 3B).   
 In order to determine the transcriptional profile of these cells, we performed 
RNA-seq in duplicate for each of these cell lines, along with a wildtype mouse 
esophageal cell line control. Reads were adjusted to sequencing read depth and then 
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quantile normalized. Fold change was determined as compared to the wildtype cells. 
Classic wildtype TP53 targets such as Mdm2 and Cdkn1A were downregulated in the 
compound mutant and null cells (data not shown). Since the TP53 null cells were also 
tumor derived, many expression changes could be attributed to the transformation 
process. Differences between the compound mutants versus the null cells may be 
attributed to direct and indirect functions of mutant TP53, although stochastic carcinogen 
induced events cannot be entirely excluded.  
 Interestingly, preliminary analysis of the RNA-seq data show an increase in 
expression of mesenchymal genes in the compound mutant cells, as compared to both the 
null cells and wildtype cells, along with a decrease in epithelial genes. Pathway analysis 
additionally indicated epithelial to mesenchymal transition (EMT) as the most 
statistically significant pathway dysregulated in both compound mutant cells, as 
compared to the null cells (data not shown). EMT is critical in development and wound 
healing but can also become co-opted during tumorigenesis to induce invasion and 
metastasis. During EMT, epithelial cells lose junctions and change cellular shape; the 
classic change of EMT includes loss of Cdh1 (E-cadherin) and gain of Cdh2 (N-
cadherin). Expression changes in Twist, Zeb1/2, Snail, Sparc, Vimentin, which have all 
previously been suggested of supporting mesenchymal phenotypes (Thiery et al., 2009; 
Lamouille et al., 2014; Vannier et al., 2013) are shown to be upregulated in the 
compound mutant cells. Correspondingly, the compound mutant cells exhibit a decrease 
in expression of genes associated with the epithelial phenotype, such as Cdh2 and Epcam, 
as compared to the TP53 null cells and wildtype control. Furthermore, Ctnnb2, the gene, 
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which encodes for the protein p120 CATENIN is highly down regulated in mutant 
compound cells. Keratins, which are associated with esophageal keratinocytes, such as 
Krt4 and Krt8 are additionally downregulated in the compound mutants, suggesting a loss 
of epithelial identity.  
 Although many of these gene targets need to be confirmed, there is indeed a trend 
toward EMT induction in the compound mutant cells. Since EMT may be critical for 
tumor cell dissemination and extravasation, future experiments will focus on the ability 
of compound mutant cells to induce metastases in a retro-orbital injection model of lung 
metastasis. In order to perform these experiments utilizing isogenic controls, we knocked 
down mutant Tp53 in both compound mutant cell lines with two different short hairpins 
against mouse Tp53 (Figure 3C). These cells will be utilized for future experiments to 
examine the role of mutant TP53 in EMT, mesenchymal to epithelial transition (MET) 
and metastasis.  
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Discussion 
 We have demonstrated that mutations in TP53, in conjunction with a 16-week 
regiment of 4-NQO in the drinking water, can lead to high-grade dysplasia and induction 
of invasive squamous cell carcinoma. Based on our tumor incidence curves, we observe 
(1) TP53 null and compound TP53 mutants demonstrate a decreased median tumor 
latency time, as compared to their heterozygote controls, and (2) TP53 compound mice 
display the fastest tumor latency as compared to all other genotypes. This first finding 
supports the notion that a wildtype copy of Tp53 can delay the onset of tumorigenesis, 
similar to patients who exhibit germ-line mutations of Tp53 at one allele (Malkin et al., 
1990). Although we have not yet sequenced the tumors from the heterozygote mice, we 
expect that loss of heterozygosity at the Tp53 loci would be necessary for full 
transformation of the tissue, as previously reported (Olive et al., 2004) Furthermore, our 
data suggest that there is no statistical difference in tumor incidence curves between 
mutant TP53 and loss of TP5 when a wildtype allele is still present. 
The second finding suggests that mutant TP53 may have oncogenic functions in 
order to induce faster progression of ESCC as compared to loss of TP53 alone. Previous 
mouse models of mutant TP53 driven carcinomas have demonstrated varied results on the 
role of mutant TP53 versus loss of TP53 alone during tumor progression. Global 
compound TP53 mutant mice, with the R172H allele, compared to TP53 null mice 
showed no difference in tumor latency, but rather, showed either a difference in tumor 
spectrum or increase in metastases potential in the TP53 compound mice (Olive et al., 
2004; Lang et al., 2004). In a mammary tumor model, driven by overexpression of WNT-
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1, addition of a humanized R175H knock-in mutation of TP53 did not potentiate faster 
tumorigenesis as compared to addition of loss of TP53. Yet the mutant compound mice 
exhibited increased number of mammary tumors as compared to the null controls (Lu et 
al., 2013). Interestingly though, in an APCfl/+ model of intestinal carcinoma, addition of a 
TP53R172H/+ allele in mice led to significant increase in invasive tumors, as compared with 
the addition of a TP53+/- allele, with no difference in overall survival (Muller et al., 2009).  
 Although our results are currently not powered to make definitive conclusions on 
the role of mutant TP53 in tumor induction and progression, we find further evidence to 
suggest that mutant TP53 may play an oncogenic roles in inducing EMT, based on our ex 
vivo RNA-seq results. Incidentally, wildtype TP53 can repress EMT through multiple 
mechanisms. Loss of TP53 has been shown to downregulate miR-200c, leading to an 
induction of an EMT program, with increases in levels of N-CADHERIN and ZEB1 
(Chang et al., 2011). TP53 can also repress the expression of SLUG, through its 
downstream target, MDM2. Slug, in turn, can promote EMT through its regulation of E-
CADHERIN and MMP-2 (Wang et al., 2009).  
Yet, in our dataset, many EMT associated genes are further deregulated in the 
TP53 compound mutant cells as compared to the TP53 null cells, suggesting additional 
roles of mutant TP53. Previous notions of GOF mutant TP53 in EMT and invasion have 
been reported. In prostate cancer cell lines, the R175H mutant has been shown to 
upregulate TWIST by alleviating repressive marks at the promoter (Kogan-Sakin et al., 
2011). Several works have additionally highlighted the role of mutant TP53 in the 
inactivation of various isoforms of TP53 family members, TP63 and TP73, in order to 
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induce invasion.  Inhibition of TAp63 through binding at the DBD by mutant TP53, leads 
to inhibition of integrin and EGFR recycling, and thus a more invasive phenotype (Muller 
et al., 2009). Moreover, TGF-β was shown to stabilize the interactions of mutant TP53 
and TP63, leading to downregulation of the TP63 targets, SHARP-1 and CCNG2, and 
cellular migration (Adorno et al., 2009). Finally, in pancreatic cancer, mutant TP53 can 
inhibit the TP73/NFY repression of PDGFRB, in order to promote invasion and 
metastasis (Weissmueller et al., 2014).  
Incidentally, our dataset did not indicate any changes in expression of Tp63 or 
Tp73, at least not in the RNA-level. However, we do observe marked increases in 
multiple mesenchymal transcription factors such as Zeb1/2, Twist1 and Snail. In addition 
to regulation of one another, these transcription factors can work both alone and in 
concert in order to induce repression CDH1 and activation of CDH2 (Montserrat et al., 
2011). Our RNA-seq data, in agreement, show that in the compound mutant cells, there is 
indeed a cadherin switch, with downregulation of CDH1 to upregulation of CDH2. 
VIMENTIN, a major cytoskeletal feature of mesenchymal cells, is additionally 
upregulated. Correspondingly, the compound mutant cells lose epithelial identity through 
the downregulation of basal and suprabasal keratins, K14 and K4, respectively.   
In ESCC, EMT can be promoted through various potential mechanisms. One of 
the most potent methods of EMT induction is through TGF-β signaling (Mani et al., 
2008; Ohashi et al., 2010b). Within a 14-day TGF- β treatment, both transformed 
epithelial cells and esophageal cancer cells can induce an E-CADHERIN to N-
CADHERIN switch, along with induction of ZEB1/2, and acquisition of a spindle shaped 
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morphology (Ohashi et al., 2010b).  NOTCH3 can inhibit the TGF- β mediated changes, 
whereas reactive oxidative species may promote the EMT (Ohashi et al., 2011; Kinugasa 
et al., 2015). Of note, the cells that undergo EMT, additionally shift cell surface marker 
expression to a CD44High- CD24Low population (Ohashi et al., 2010a; Mani et al., 2008). 
These markers have previously been implicated as putative cancer stem cell markers. Our 
RNA-seq data set do not indicate a strong inclination towards increased Cd44 expression 
in the compound mutant cells, although we do see a marked decreased in Cd24 
expression. Yet, Cd44 induction may be regulated at the protein level, and thus it would 
be of interest to investigate the protein expression of CD44 in the compound mutant cells 
as compared to null cells through fluorescence-activated cell sorting-analysis. In addition 
to promoting metastases and potentially cancer stem cell-like phenotypes, EMT can also 
induce increased tumor budding in ESCC. Tumor budding, which is a poor prognostic 
marker in ESCC, describes isolated cells out side the margin of a tumor and is associated 
with high levels of VIMENTIN and low levels of E-CADHERIN (Niwa et al., 2014). 
Future directions will focus on the effect of mutant TP53 on EMT, invasion, and 
metastasis. In addition to generating more tumor-derived cell lines of both compound 
mutant TP53 cells and TP53 null cells, we will perform quantitative PCR to validate the 
EMT gene signature derived from our RNA-seq. Since EMT has also been associated 
with a more stem-like phenotype, we will also determine if changes in stemness markers 
are affected in the compound mutant TP53 cells at the protein level, as we did not detect 
changes in the RNA-level (Mani et al., 2008). These acquired stemness properties by 
EMT cells are also critical for survival during the extravasation process, and eventual 
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metastasis. We will functionally test if compound mutant TP53 cells can produce 
metastasis in a retrooribtal injection model of lung metastasis. Knockdown of mutant 
TP53 has been previously reported to decrease metastatic potential to both the lung and 
liver in a pancreatic cancer model (Weissmueller et al., 2014). Our experiments will 
validate the potentially crucial role of mutant TP53 in mediating EMT, metastasis and 
overall poorer survival in ESCC.  
Finally, we plan to mechanistically decipher the role of mutant TP53 in ESCC, 
and determine if mutant TP53 affects EMT-associated genes in a direct or indirect 
manner. We will perform a ChIP-seq for mutant TP53 in the compound mutant cell lines. 
Since, wildtype TP53 is deleted through recombination, we would specifically be 
immunonopercipitating for mutant TP53. This data set in combination with our RNA-seq 
results could indicate future direct targets of mutant TP53, and its potential GOF 
properties.  
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Materials and methods 
Generation of mouse model  
The Institutional Animal Care and Use Committee (IACUC) at the University of 
Pennsylvania approved all animal studies. L2-Cre transgenic mice were generated by 
cloning Cre recombinase under the control of the EBV ED-L2 promoter (Nakagawa et 
al., 1997; Opitz et al., 2002) and were genotyped as previously described (Stairs et al., 
2011). TP53R17H, TP53fl and RosaYFP mice have previously been described (Olive et al., 
2004; Marino et al., 2000; Srinivas et al., 2001). 4-nitroquinoline 1-oxide (4-NQO) 
experiments were performed as described previously (Tang et al., 2004; Long et al., 
2015). In brief, 8 to 12-week-old mixed background mice, bearing the L2-Cre, Tp53 
mutant and/or wildtype alleles, and YFP transgene were given 10mg/ml of 4-NQO 
diluted in 10% propylene glycol in their drinking water ad libitum. Mice were euthanized 
either directly after 16-weeks of treatment or during the 12-week wash out period. 
Tissues were processed for histology and immunohistochemistry (IHC) or cell lines were 
generated from the tumor tissue.  
Histology and immunohistochemistry (IHC) 
Tumor tissue were embedded in paraffin blocks and cut in 5 µM sections. 
Hematoxlyin and eosin (H&E) and IHC staining were performed as previously described 
(Long et al., 2015). All histology was read blinded by an independent pathologist. 
Paraffin embedded sections were incubated with mouse TP53 antibody (CM5, Vector 
Labs, Burlingame, CA 1:250).  
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Cell isolation and culture 
Tumor derived cancer cells were generated as previously described (Stairs et al., 
2011). In brief, freshly isolated esophageal tumors were digested in dispase (Thermo 
Fisher Scientific, Waltham, MA) for 10 minutes at 37° on a shaker. Esophagi tumors 
epithelial cells were then peeled from the submucosa and subjected to incubation in 
trypsin-EDTA (Thermo Fisher Scientific) for 10 minutes at 37° on a shaker. Detached 
cells were filtered through a 40 µM strainer into soybean trypsin inhibitor (Thermo Fisher 
Scientific). Cells were then centrifuged and resuspended and plated in calcium-free 
keratinocyte serum-free media (Invitrogen, Carlsbad, CA), supplemented with 40  µg/ml 
of bovine pituitary extract, 1ng/ml epidermal growth factor, 18 µM of CaCl2, and 1% 
penicillin/streptomycin. Short hairpins against murine TP53, cloned into the pLKO.1 
vector were a gift from Dr. Berger. Lentiviral spinfection was performed as described 
previously on cultured tumor cell lines (Michaylira et al., 2010). Lentiviral infected cells 
were selected in 2 µg/mL of puromycin. Knockdown was confirmed via western blot.  
RNA isolation and sequencing 
 Cells were grown to 80% confluency in 10 cm dishes.  Cells were harvested and 
polyA+ mRNA was isolated by double selection with mRNA Direct Dynabeads 
(Invitrogen).  PolyA+ mRNA were fragmented to an average size of 200bp using Mg2+-
containing buffers at 94˚C for 15 minutes.  First-strand synthesis was performed using 
Protoscript II reverse transcriptase and random hexamer primers (New England Biolabs, 
Ipswich, MA).  Directional second-strand synthesis was performed using the dUTP 
method (New England Biolabs).  End-repair, adapter ligation, and 12 cycles of PCR were 
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performed as per the NEBnext Ultra protocol to produce barcoded, Illumina-compatible 
sequencing libraries.  Insert size distribution was measured using the Agilent Bioanalyzer 
(Agilent Technologies, Santa Clara, CA) and sequencing library molarity was quantified 
by the Kapa method using absolute quantification standards. Reads were mapped as 
previously described (Sammons et al., 2015). Relative reads were normalized to the 
wildtype cell line.  
Western blot   
To confirm protein expression, western blotting was performed as previously 
described (Long et al., 2015). Proteins were separated through a 4–12% sodium dodecyl 
sulfate–polyacrylamide gel electrophoresis Bis-Tris gel (Invitrogen) and transferred to a 
polyvinylidene difluoride membrane (Immobilon-P; Millipore, Billerica, MA). 
Membranes were blocked with 5% non-fat milk in TBS-T (1× TBS and 0.01% Tween-
20), probed with primary antibody (1:1000 TP53 CM5, Vector Labs, 1:1000 GAPDH, 
Millipore), diluted in blocking buffer overnight at 4°C, washed with TBST-T and 
incubated with horseradish peroxidase-coupled secondary antibodies (GE Healthcare, 
Pittsburgh, PA). Signal was visualized with Amersham ECL-Prime (GE Healthcare) as 
per manufacturer’s instructions.   
  
	  
	  
79	  
 
 
 
 
 
 
 
 
Figures and figure legends 
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Figure 1 
 
Figure 1. Mutations in TP53 with 4-NQO can induce dysplasia and invasive 
squamous carcinoma of the esophagus (A) Schematic of experimental treatment plan 
indicating genotypes of mice and time period of 4-NQO treatment. (B-G) Representative 
Hematoxylin and Eosin (H&E) images of the esophagus after 16-weeks of 4-NQO 
treatment in (B) TP53+/+ (C) TP53+/- (D) TP53R172H/+ (E) TP53-/- (F-G) TP53R172H/- mice. 
Scale bars represent 100 µM.  
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Figure 1 
 
Figure 1. Mutations in TP53 with 4-NQO can induce dysplasia and invasive 
squamous carcinoma of the esophagus. (H-J) Representative TP53 staining of mouse 
tumors. (H) No antibody control (I) staining in a TP53-/- tumor and (J) staining in a 
TP53R172H/- tumor. Bars represent 100 µM (K-L) Representative images of esophageal 
tumors in (K) brightfield and with (L) YFP filter. Bars represent 5 mM.  
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Figure 2 
	  
Figure 2.  Mutations in TP53 with 4-NQO can lead to invasive squamous carcinoma 
of the esophagus and metastasis to the lymph node and lung (A) Schematic of 
experimental treatment plan indicating genotypes of mice and time period of 4-NQO 
treatment along with washout period with normal drinking water. (B-C) Tumor incidence 
curves of (B) TP53-/+ and TP53R172H/+ mice and (C) TP53-/- and TP53R172H/- mice. No 
statistical difference is seen in tumor incidence between TP53-/+ and TP53R172H/+ mice. 
Difference in tumor incidence curve between TP53-/- and TP53R172H/- mice is statistically 
significant based on Gehan–Breslow–Wilcoxon test (P= 0.04).  
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Figure 2 
 
Figure 2.  Mutations in TP53 with 4-NQO can lead to invasive squamous carcinoma 
of the esophagus and metastasis to the lymph node and lung. (D-F) Representative 
images of lymph nodes from tumor-burdened mice in (D) bright field (E) YFP-filter and 
(F) H&E stained. (G) Representative H&E of micrometastsis of squamous cell carcinoma 
in lung parenchyma. Bars in (D-E) represent 5 mM and (F-G) represent 10 µM.  
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Figure 3 
 
 
Figure 3.  Isolation of cells from mouse tumors.  (A) Representative images of cells 
isolated from an TP53R172H/-  tumor, which displays a mix of epithelial and spindle-shaped 
morphology. Brightfield and YFP filtered images are shown at x200. (B) Western blot for 
TP53 (1:1000, CM5) and GAPDH (1:1000) in two different TP53R172H/- cell lines and one 
TP53-/-  cell line. (C) Western blot for TP53 and GAPDH after lentiviral transduction of 
pLKO.1 shSCR or shp53 constructs were stably expressed in both TP53R172H/- cell lines.  
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Tables and table legends 
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 Table 1 
Mesenchymal	  
Genes	   	  	   	  	   	  	   	  	  
Gene	   R172H/-­‐	  (1)	   R172H/-­‐	  (2)	   -­‐/-­‐	   +/+	  
Cdh2	   59.81751582	   49.93173493	   3.444777445	   1	  
Itga5	   1.595422603	   0.807512798	   0.695034127	   1	  
Serpine1	   1.444222711	   4.071795564	   4.117733044	   1	  
Slug	   1.049709519	   0.845504489	   1	   1	  
Snail	   105.1897074	   2.328456105	   1.625126135	   1	  
Sparc	   19.49080083	   28.36893606	   7.4036831	   1	  
Twist1	   1.721886975	   2.645723427	   0.891134343	   1	  
Twist2	   2.753315833	   12.92097264	   8.604172423	   1	  
Vimentin	   1429.164941	   3116.429364	   281.908284	   1	  
Zeb1	   51.68922707	   84.34181017	   6.646976372	   1	  
Zeb2	   9.869476577	   6.45025041	   1.243385188	   1	  
 
Table 1: Genes associated with a mesenchymal gene signature. Genes that are highly 
upregulated in the TP53R172H/- samples as compared to both the TP53-/- and TP53+/+ cells 
are hi-lighted in green. All values are expressed as fold change over reads in TP53+/+ 
cells.  
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Table 2 
Epithelial	  Genes	   	  	   	  	   	  	   	  	  
Gene	   R172H/-­‐	  (1)	   R172H/-­‐	  (2)	   -­‐/-­‐	   +/+	  
Cdh1	   0.275625757	   0.131802502	   1.009409766	   1	  
Ctnnd1	   0.303491284	   0.366940979	   0.950726541	   1	  
Epcam	   0.331532412	   0.158274311	   1.687692594	   1	  
Krt13	   0.467276157	   1.206878537	   4.874677115	   1	  
Krt14	   0.369974044	   0.731272017	   0.524183085	   1	  
Krt16	   0.069929071	   0.294211673	   0.7342291	   1	  
Krt18	   0.36366366	   0.456454908	   2.343444473	   1	  
Krt4	   0.091537358	   0.373060373	   12.34202634	   1	  
Krt5	   1	   1.367480195	   1	   1	  
Krt7	   0.214104185	   0.056027745	   1.126921409	   1	  
Krt8	   0.109274725	   0.046238564	   1.515886557	   1	  
Zo1	   0.442191461	   0.521262106	   0.803381473	   1	  
 
Table 2: Genes associated with an esophageal epithelial gene signature. Genes that 
are highly downregulated in the TP53R172H/- samples as compared to both the TP53-/- and 
TP53+/+ cells are hi-lighted in pink. All values are expressed as fold change over reads in 
TP53+/+ cells.  
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CHAPTER 4: Thesis summary and discussion 
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 The focus of this thesis was to describe the multiple mechanisms, in which 
esophageal squamous cell carcinoma (ESCC) pathogenesis can occur and the 
consequences of such genetic perturbations. Indeed the initial emphasis of this project 
was on the role of mutant TP53, as it is the most commonly mutated gene in cancer and 
in ESCC (Song et al., 2014; Gao et al., 2014). Previous in vitro work utilizing novel 
transformed esophageal cell systems and in vivo like 3D organotypic (OTC) cultures laid 
the groundwork for this project (Okawa et al., 2007; Michaylira et al., 2010). Mutant 
TP53, when over expressed, in cooperation with overexpression of other oncogenes such 
as EGFR and CYCLIN D1, can lead to enhancement of tumorigenic properties, such as 
increased proliferation, migration, invasion, anchorage-independent growth and even 
tumor formation in nude mice (Okawa et al., 2007; Michaylira et al., 2010; Ohashi et al., 
2010b).  
In vitro studies of mutant TP53-mediated invasion led to the investigation of the 
role of WNT signaling in ESCC and how specifically WNT10A plays a role during 
tumorigenesis. WNT10A was discovered to be upregulated in an invasive gene signature 
microarray in EPC2-hTERT-EGFR-TP53R175H cells. Although we did not find a direct 
relationship between mutant TP53 and WNT10A, we did observe that WNT10A could 
act as an oncogene in ESCC, in its own respect. Of note, our RNA-seq dataset, derived 
from mouse tumor-derived cancer cells, show that, although Wnt10a was not upregulated 
significantly between TP53R172H/- and TP53-/- cells, there was at least a 2-fold increase in 
Wnt10a expression levels in all three cancer cell lines as compared to wildtype 
esophageal cells (data not shown). Wnt6 and Wnt10b were incidentally also upregulated 
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in the cancer cell lines, based on RNA-seq data. WNT10A and WNT10B may have 
redundant functions, as they are closely related paralogs, induced by a duplication event 
at the last common ancestor of jawed-vertebrates. WNT6, is also frequently co-
transcribed with WNT10A, as they reside at the same genetic loci with no intervening 
genes (Nusse, 2001). Although we did not actively pursue the impact of these other 
closely related WNTs in our studies, we did note that in EPC2-hTERT-EGFR-TP53R175H 
transformed cells, WNT10B was also prominently upregulated via quantitative PCR, as 
compared to control cells (data not shown). 
Our emphasis on WNT10A demonstrated that its upregulation could be used as an 
indicator for poor prognosis in ESCC.  High levels of WNT10A staining in a tumor 
microarray (TMA) indicated a significant reduction in overall survival, as well as a 
halved median survival time, when compared to low levels of WNT10A staining.  In fact, 
WNT10A staining was rarely present in normal tissue. We showed through 
immunohistochemistry (IHC) staining for WNT10A that this protein was additionally 
upregulated in 4-Nitroquinoline 1-oxide  (4-NQO) induced hyperplasia and dysplasia of 
the esophagus. Staining for WNT10A in the 4-NQO induced compound mutant TP53 
mice also showed high WNT10A expression levels in the invasive squamous carcinoma 
regions (data not shown). WNT10A expression was additionally highly upregulated in a 
panel of ESCC cancer cell lines, when compared to normal wildtype cells. It would be 
interesting to determine if WNT10A knockout mice would have the same propensity for 
tumor induction and latency as wildtype mice, when treated with 4-NQO. This 
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experiment could impart an in vivo role for WNT10A in ESCC tumorigenesis, and 
complement the human data and in vitro functional studies.   
Finally, we show in chapter 2 the definitive role of WNT10A as functionally as an 
oncogene in ESCC, by promoting proliferation, migration, invasion, and stemness 
properties. These findings recapitulate previous reports of WNT10A as a driver in 
tumorigenesis in renal cell carcinoma (Hsu et al., 2012). In these studies, WNT10A can 
induce canonical WNT signaling, in order to induce stabilization of nuclear Β-
CATENIN, in order to drive downstream targets such as CCND1. Our results indicate 
that over-expression of WNT10A can increase B-CATENIN levels, but we have yet to 
confirm the activation of this signaling pathway, as reporter assays are hindered by the 
difficulty of transient transfection in our primary keratinocyte cell line. Future studies 
would focus on the downstream effects of WNT10A, such as its ability to induce the 
canonical WNT signaling pathway, which receptors are utilized by WNT10A in ESCC, 
and how WNT10A is being regulated in ESCC. 
Previous 3D OTC invasion assays performed in the transformed esophageal cells, 
demonstrated the variability of the different mutant TP53s in their ability to induce 
invasion and hinted at the potential gain of function (GOF) roles of mutant TP53 in 
ESCC. Nevertheless, all previous experiments utilized overexpression of mutant TP53 in 
the presence of a wildtype TP53 allele. This experimental setup did not exclude potential 
dominant negative functions of mutant TP53. In order to fully study the potential GOF 
roles of mutant TP53, we realized the necessity to perform all future experiments in a 
TP53 null background. We therefore chose to utilize Cre-Lox recombination mouse 
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model systems to knockout wildtype Tp53, while introducing the R172H missense 
mutation. R172H, which is the mouse homologue of the human R175H hotspot mutation, 
was chosen because it had previously been described to promote carcinoma formation 
and increase metastasis (Olive et al., 2004; Lang et al., 2004). Additionally, the R175H 
mutation induces the highest degree of invasion in the 3D OTC model (Okawa et al., 
2007). R175H is also one of the two most commonly mutated sites of TP53 in ESCC, and 
it had the unique property of being a conformational altering mutant (Petitjean et al., 
2007). By altering the conformation of the folded TP53 protein, the R175H mutation can 
expose new epitopes for potential novel protein-protein or protein-DNA interactions 
(Bullock and Fersht, 2001).  
 Ultimately, our goal was to generate a mutant TP53-driven mouse model of 
ESCC, in order to study its role in tumorgenesis. Unfortunately, the murine esophagus 
has many protective barriers, which inhibit transformation. Previous genetic based mouse 
models of ESCC frequently require a 9-18 month tumor latency period, indicating the 
resistance of this tissue to transformation (Stairs et al., 2011; Andl et al., 2014). 
Additionally, the epithelium of the mouse esophagus is keratinized, unlike that in human 
esophagus, which provides additional protection from extracellular insults. We found that 
with L2-Cre driven Tp53 mutation alone, mice displayed relative normal morphology in 
the esophagus. Therefore, we found a necessity to challenge the TP53 mutant mice with 
additional carcinogenic insults. 4-NQO was utilized, as it had previously been shown to 
induce invasive squamous cell carcinoma of the tongue and esophagus (Tang et al., 
2004). Our utilization of a genetic and environmental-based model of mouse ESCC may 
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in fact be more physiological to human disease, as multi-factorial components contribute 
to the pathogenesis of human ESCC.  
 Our overall findings indicate that compound mutations in TP53 indeed accelerate 
the pathogenesis of ESCC in our mouse model, as compared to wildtype mice treated 
with 4-NQO alone. The dynamics of tumor latency amongst the different alleles is still an 
area of ongoing investigation, as we do not see differences in tumor incidence curves in 
TP53R172H/+ mice versus TP53-/+ and the differences that we do see in tumor incidences 
between TP53R172H/- and TP53-/- , although significant, requires increase number of mice 
to power the study. Of note, previous findings in different mouse models of cancer that 
are driven by mutant TP53, showed no difference in tumor latency or survival when 
comparing TP53R172H/- mice versus TP53-/- mice (Muller et al., 2009; Lu et al., 2013; 
Weissmueller et al., 2014; Ahronian et al., 2015).  
Nevertheless, our mouse model generated additional tools for future studies on 
mutant TP53 GOF as well as pathogenesis of ESCC. As we aged the mice longer beyond 
the 16-week 4-NQO-treatment period, we found that our mice were able to develop 
lineage-labeled metastasis to the periaortic and cervical lymph node and lungs. Another 
area of active investigation is the role of mutant TP53 on induction of metastasis. 
Although we are able to generate metastasis amongst our TP53 mutant mice, our system 
is currently flawed to study this phenomenon. Firstly, since we are utilizing a carcinogen, 
mutations may be stochastic and the specific role of mutant TP53 in inducing invasion 
and metastasis may be unclear. Secondly, the dynamics of primary esophageal tumor 
growth hinder our ability to study metastasis as an isolated model, since depending on 
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primary tumor growth patterns (intramural versus extramural growth), mice may be 
required to be euthanized before metastasis can occur.  Therefore, an accurate 
interpretation of the extent of metastasis would require extremely large number of mice, 
when comparing multiple genotypes. In order to simplify the system, we plan to utilize a 
retro-orbital injection model to study metastatic potential of various tumor-derived 
mutant TP53 cell lines. The dissemination pattern of retro-orbital injection leads to lung 
metastasis, which is one of the primary metastatic niches of ESCC. Compound mutant 
TP53 cells can further be genetically manipulated, such as through knockdown of the 
mutant allele to generate isogenic TP53 null control cells. Additionally, specific targets of 
mutant TP53 may also be perturbed genetically, in order to examine downstream 
mechanisms of mutant TP53 functions.  
From the lineage-labeled tumor derived cell lines that we have generated from our mouse 
model, we have obtained RNA-seq data comparing wildtype, non-tumorigenic cells, to 
TP53-/- and TP53R172H/- cancer cells. Since the TP53-/- and TP53R172H/- have been exposed 
to additional mutagenic changes through 4-NQO treatment, and have undergone a 
selection process through the culturing system, we decided to prioritize our focus on 
genes that were specifically affected in the TP53R172H/-, but remain unaffected in the 
TP53-/- cells. This experiment is a first pass examination of the transcriptome changes 
that TP53R172H mutation may induce in ESCC. From a cursory examination of the data, 
we have determined that a set of EMT-associated genes is highly dysregulated in the 
TP53R172H/- cells. This finding supports our hypothesis that mutant TP53 may play a GOF 
role in mediating invasion and metastasis in ESCC. In order to fully determine direct 
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mechanisms of mutant TP53 GOF functions, we plan to perform a mutant TP53 
chromatin immuneprecipitation sequencing (ChIP-seq) for novel mutant TP53 targets. 
Previous labs have performed either ChIP-seq or RNA-seq in different mutant TP53 
expressing cell lines in order to discover components of the mutant TP53 transcriptome 
(Do et al., 2012; Freed-Pastor et al., 2012; Garritano et al., 2013; Xiong et al., 2014). 
These datasets have utilized different mutations of TP53 and in different cancer cell 
contexts. From these studies, it was shown that mutant TP53 may have a propensity to 
localize at ETS-binding sites. Yet these studies also demonstrate the unique role of 
mutant TP53 GOF properties, which may be both cell-type specific as well as mutant 
specific. Analysis of our RNA-seq data set may indicate specific transcription factor 
signatures that are being co-opted by mutant TP53 in ESCC, through protein-protein 
interactions. By interrupting these interactions either through knockdown of the partner 
transcription factor or re-activation of wildtype TP53 through a small molecule 
compound, we may curtail the GOF effects of mutant TP53.  
Our in vivo model of murine ESCC is reproducible, fast, and highly specific to 
esophageal lesions. The lineage label in our ESCC model also allows for ex vivo cell 
sorting as well as tracing of primary and metastatic lesions. Potentially, this mouse model 
can be utilized in the future, not only to study different components of mutant TP53 
induced ESCC, but also be used as mouse model for therapeutic studies.  
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